var title_f1_8_1152="Rhomboid flap";
var content_f1_8_1152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F77521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F77521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Rhomboid flap",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A single rhomboid flap is very useful for defects that cannot be closed directly and abut an area of laxity. The orientation of the rhomboid is designed so that the flap donor site will close easily once the flap is transposed. Each rhomboid offers the possibility of four flap choices, each arising from the short axis of the rhomboid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_8_1152=[""].join("\n");
var outline_f1_8_1152=null;
var title_f1_8_1153="QRS alignment methods";
var content_f1_8_1153=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    QRS alignment methods",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 430px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Optimal beat alignment permits the averaging of signals at physiologically corresponding timepoints. Sliding template alignment provides the greatest precision and may be computed by maximizing the dot-product between candidate beats and a template. QRS peak and upstroke fiducial methods are less precise but still used. The P-wave triggered signal averaged ECG requires P-wave alignment, typically with a sliding template approach.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_8_1153=[""].join("\n");
var outline_f1_8_1153=null;
var title_f1_8_1154="3D SHAX view of classic MVP";
var content_f1_8_1154=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1176px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/83605/3D_SHAX_classic_MVP_video.mp4?title=3D+SHAX+view+of+classic+MVP\" style=\"width:512px;height:368px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Three-dimensional short-axis echocardiographic view of classic mitral valve prolapse with bileaflet prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Images from a patient with classic Barlow's disease. Note diffusely thickened anterior and posterior leaflets, with massive prolapse mostly of the P2-P3 scallops.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_8_1154=[""].join("\n");
var outline_f1_8_1154=null;
var title_f1_8_1155="Relationship of development to stem cell type";
var content_f1_8_1155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Relationship of development to stem cell type",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Types of stem cells and their relationship to normal development. Totipotent stem cells are thought to exist only in the first several divisions of the zygote. Stem cells become more restricted as pluripotent cells once the blastocyst is formed. By the time the primitive streak forms, most cell types in the organism become further restricted to multipotent status, with the exception of embryonic germ cell lines. The cells derived from these later stages in development have been called \"embryonic\" or \"adult\" stem cells, to reflect their different potency as stem cells. The unilinear relationship of development to stem cell potential that is depicted here is no longer a rigid dictate as it appears that highly differentiated cells can be reprogrammed to become pluripotent cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn based on information from The National Institutes of Health.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_8_1155=[""].join("\n");
var outline_f1_8_1155=null;
var title_f1_8_1156="Paget disease of the L hemipelvis and L proximal femur";
var content_f1_8_1156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Paget disease of the L hemipelvis and L proximal femur",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Paget disease of the L hemipelvis and L proximal femur (sparing the R) with coarse remodeling of bone, enlargement and deformity of the pelvis. There is thickenening of the iliopectineal line so characteristic of PDB, with accentuated trabeculae and thickened cortices. Protrusio and loss of joint space are present on the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Margaret Seton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_8_1156=[""].join("\n");
var outline_f1_8_1156=null;
var title_f1_8_1157="Disopyramide: Patient drug information";
var content_f1_8_1157=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Disopyramide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     see \"Disopyramide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/53/30550?source=see_link\">",
"     see \"Disopyramide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Norpace&reg;;",
"     </li>",
"     <li>",
"      Norpace&reg; CR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Norpace&reg;;",
"     </li>",
"     <li>",
"      Rythmodan&reg;;",
"     </li>",
"     <li>",
"      Rythmodan&reg;-LA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700629",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used to treat unsafe fast heartbeats only. It may cause risky side effects. You will be closely watched when starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a fast heartbeat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to disopyramide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703806",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have poor electrical activity in the heart without a working pacemaker.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697334",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have prostate disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12389 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-36135ECCB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_8_1157=[""].join("\n");
var outline_f1_8_1157=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161671\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161672\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029078\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029080\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029079\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029084\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029085\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029087\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029082\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029083\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029088\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029089\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=related_link\">",
"      Disopyramide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/53/30550?source=related_link\">",
"      Disopyramide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_8_1158="Calcified apical caps PA";
var content_f1_8_1158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bilateral calcified apical caps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral calcified apical caps, unrelated to asbestos exposure. Pleural plaques usually spare the apices.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_8_1158=[""].join("\n");
var outline_f1_8_1158=null;
var title_f1_8_1159="Modafinil: Drug information";
var content_f1_8_1159=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Modafinil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/26/28069?source=see_link\">",
"    see \"Modafinil: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/20/38214?source=see_link\">",
"    see \"Modafinil: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F197665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Provigil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F197666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alertec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F197693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Central Nervous System Stimulant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F197669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS):",
"     </b>",
"     Oral: Initial: 200 mg as a single daily dose in the morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Shift work sleep disorder (SWSD):",
"     </b>",
"     Oral: Initial: 200 mg as a single dose taken ~1 hour prior to start of work shift",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses up to 400 mg daily, given as a single dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Narcolepsy:",
"     </b>",
"     Oral: Initial: 200 mg daily in 2 divided doses (first dose in the morning and second dose at noon [or no later than early afternoon]); may titrate dose upward in 100 mg increments as needed and tolerated (maximum single dose: &lt; 300 mg; maximum daily dose: 400 mg). Single doses &ge;300 mg and daily doses &gt;400 mg are associated with increased side effects and are not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Obstructive sleep apnea:",
"     </b>",
"     Oral: 200 mg once daily in the morning.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Shift work sleep disorder:",
"     </b>",
"     Oral: 200 mg as a single dose taken ~1 hour prior to start of work shift",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Unlabeled use:",
"      </i>",
"     </b>",
"     <b>",
"      ADHD:",
"     </b>",
"     100-400 mg daily (Taylor, 2000)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F197670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elimination of modafinil and its metabolites may be reduced as a consequence of aging and as a result, consider initiating at lower doses in this patient population.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F197671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling (insufficient data).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F197672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hepatic impairment: Dose should be reduced to one-half of that recommended for patients with normal liver function.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F197647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Provigil&reg;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Provigil&reg;: 200 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F16564662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alertec&reg;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F197632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F197695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10961086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM231722.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM231722.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11305814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     For the treatment of narcolepsy and obstructive sleep apnea/hypopnea syndrome, administer dose in the morning. For the treatment of shift work sleep disorder, administer dose ~1 hour prior to start of work shift.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     For the treatment of narcolepsy, administer in 2 divided doses with first dose given in the morning and the second dose given at noon (or no later than early afternoon) to avoid potential for insomnia. For treatment of obstructive sleep apnea, administer as a single dose in the morning. For the treatment of shift work sleep disorder, administer dose ~1 hour prior to start of work shift.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F197648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy and shift work sleep disorder (SWSD); adjunctive therapy for obstructive sleep apnea/hypopnea syndrome (OSAHS)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F197690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Attention-deficit/hyperactivity disorder (ADHD); treatment of fatigue in MS and other disorders",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F197691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (adults 34%; children 20%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Appetite decreased (children 16%), abdominal pain (children 12%), nausea (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (3%), hypertension (3%), palpitation (2%), tachycardia (2%), vasodilation (2%), edema (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Nervousness (7%), dizziness (5%), anxiety (5%; dose related), insomnia (5%), depression (2%), somnolence (2%), chills (1%), agitation (1%), confusion (1%), emotional lability (1%), vertigo (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1%; includes some severe cases requiring hospitalization)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (6%), dyspepsia (5%), weight loss (children 5%), xerostomia (4%), anorexia (4%), constipation (2%), flatulence (1%), mouth ulceration (1%), taste perversion (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Abnormal urine (1%), hematuria (1%), pyuria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Eosinophilia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: LFTs abnormal (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (6%), paresthesia (2%), dyskinesia (1%), hyperkinesia (1%), hypertonia (1%), neck rigidity (1%), tremor (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Amblyopia (1%), eye pain (1%), vision abnormal (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (7%), pharyngitis (4%), lung disorder (2%), asthma (1%), epistaxis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (4%), thirst (1%), diaphoresis (1%), herpes simplex infection (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Agranulocytosis, anaphylactic reaction, angioedema, DRESS syndrome, erythema multiforme, hypersensitivity syndrome (multiorgan), mania, psychosis, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F197651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to modafinil, armodafinil, or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Patients in agitated states or with severe anxiety",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F197636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May impair the ability to engage in potentially hazardous activities. The degree of sleepiness should be reassessed frequently; some patients may not return to a normal level of wakefulness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic effects (severe): Serious and life-threatening rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported with modafinil. Although initially reported in children during clinical trials, postmarketing cases have occurred in both children and adults. Most cases have occurred within the first 5 weeks of therapy; however, rare cases have occurred after long-term use. No risk factors have been identified to predict occurrence or severity. Patients should be advised to discontinue at first sign of rash. As a result of these serious dermatologic adverse events, approval for the use of modafinil in children for ADHD was denied by the FDA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Rare cases of multiorgan hypersensitivity reactions in association with modafinil use and lone cases of angioedema and anaphylactoid reactions with armodafinil have been reported. Signs and symptoms are diverse, reflecting the involvement of specific organs. Patients typically present with fever and rash associated with organ-system dysfunction. Patients should be advised to report any signs and symptoms related to these effects; discontinuation of therapy is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use is not recommended in patients with a history of angina, cardiac ischemia, recent history of myocardial infarction, left ventricular hypertrophy, or patients with mitral valve prolapse who have developed mitral valve prolapse syndrome with previous CNS stimulant use. Increase monitoring in patients with hypertension; additional therapy may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage reduction is recommended in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disorders: Use with caution in patients with pre-existing psychosis or bipolar disorder (may induce mixed/manic episode). May exacerbate symptoms of behavior and thought disorder in psychotic patients; new onset psychosis or mania may occur with stimulant use; observe for symptoms of aggression, hostility, or suicidal ideation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep disorders: Appropriate use: For use following complete evaluation of sleepiness and in conjunction with other standard treatments (eg, CPAP). The degree of sleepiness should be reassessed frequently; some patients may not return to a normal level of wakefulness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tourette's syndrome: Use with caution in patients with Tourette's syndrome; stimulants may unmask tics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Modafinil is not FDA-approved for use in pediatrics for any indication. Serious skin reactions and psychiatric events have been observed in pediatric patients treated with modafinil. The serious nature of these adverse effects resulted in the FDA&rsquo;s Pediatric Advisory Committee unanimously recommending that a specific warning against the use of modafinil in children be added to the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F197688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2A6 (weak), CYP2C19 (strong), CYP2C9 (weak), CYP2E1 (weak), CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (weak/moderate), CYP2B6 (weak/moderate), CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F197641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Modafinil may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a strong CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Modafinil may decrease the serum concentration of Contraceptives (Estrogens).  Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with modafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Modafinil may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Strong) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F197661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid or limit ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Delays absorption, but does not affect bioavailability.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F197642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F197654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryotoxic effects have been observed in some, but not all animal studies. There are no adequate and well-controlled studies in pregnant women; use only when the potential risk of drug therapy is outweighed by the drug's benefits.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to register pregnant patients exposed to modafinil by calling 1-866-404-4106.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Efficacy of steroidal contraceptives (including depot and implantable contraceptives) may be decreased; alternate means of contraception should be considered during therapy and for 1 month after modafinil is discontinued.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F197674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F197653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Modafinil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $662.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (30): $1000.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Provigil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $882.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (30): $1332.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F197644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Levels of sleepiness; blood pressure in patients with hypertension; body mass index and weight loss; development of severe skin reactions; development or exacerbation of psychiatric symptoms (eg, agitation, anxiety, depression)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     When used for the treatment of ADHD, thoroughly evaluate for cardiovascular risk. Monitor heart rate, blood pressure, and consider obtaining ECG prior to initiation (Vetter, 2008).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F197655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Activigil (UY);",
"     </li>",
"     <li>",
"      Alertex (CN, EC);",
"     </li>",
"     <li>",
"      Modanil (KP);",
"     </li>",
"     <li>",
"      Modasomil (AT, CH);",
"     </li>",
"     <li>",
"      Modavigil (AU, NZ);",
"     </li>",
"     <li>",
"      Modiodal (DK, ES, FR, GR, MX, NL, NO, PT, SE, TR);",
"     </li>",
"     <li>",
"      Provake (IN);",
"     </li>",
"     <li>",
"      Provigil (BE, GB, IE, IL, IT, PY, TW);",
"     </li>",
"     <li>",
"      Vigia (CO);",
"     </li>",
"     <li>",
"      Vigicer (AR);",
"     </li>",
"     <li>",
"      Vigil (CZ, DE, PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F197635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The exact mechanism of action is unclear, it does not appear to alter the release of dopamine or norepinephrine, it may exert its stimulant effects by decreasing GABA-mediated neurotransmission, although this theory has not yet been fully evaluated; several studies also suggest that an intact central alpha-adrenergic system is required for modafinil's activity; the drug increases high-frequency alpha waves while decreasing both delta and theta wave activity, and these effects are consistent with generalized increases in mental alertness",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F197650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Modafinil is a racemic compound (10%",
"     <i>",
"      d",
"     </i>",
"     -isomer and 90%",
"     <i>",
"      l",
"     </i>",
"     -isomer at steady state) whose enantiomers have different pharmacokinetics",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~60%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; multiple pathways including CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Effective half-life: 15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as metabolites, &lt;10% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Biederman J and Pliszka SR, &ldquo;Modafinil Improves Symptoms of Attention-Deficit/Hyperactivity Disorder Across Subtypes in Children and Adolescents,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2008, 152(3):394-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1159/abstract-text/18280848/pubmed\" id=\"18280848\" target=\"_blank\">",
"        18280848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broughton, RJ, &ldquo;Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Modafinil in the Treatment of Excessive Daytime Sleepiness in Narcolepsy,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 49(2):444-451.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1159/abstract-text/9270575/pubmed\" id=\"9270575\" target=\"_blank\">",
"        9270575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grozinger M, &ldquo;Interaction of Modafinil and Clomipramine as Comedication in a Narcoleptic Patient,&rdquo;",
"      <i>",
"       Clin Neuropharmacol",
"      </i>",
"      , 1998, 21(2):127-129.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1159/abstract-text/9579300/pubmed\" id=\"9579300\" target=\"_blank\">",
"        9579300",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumar R, &ldquo;Approved and Investigational Uses of Modafinil: An Evidence-Based Review,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2008, 68(13):1803-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1159/abstract-text/18729534/pubmed\" id=\"18729534\" target=\"_blank\">",
"        18729534",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Attention Deficit Hyperactivity Disorder, The NICE Guideline on Diagnosis and Management of ADHD in Children, Young People and Adults,&rdquo; National Clinical Practice Guideline Number 72, 2008:1-664. Available at  www.nice.org.uk/cg072.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwartz JR, &ldquo;Modafinil in the Treatment of Excessive Sleepiness,&rdquo;",
"      <i>",
"       Drug Des Devel Ther",
"      </i>",
"      , 2009, 2:71-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1159/abstract-text/19920895/pubmed\" id=\"19920895\" target=\"_blank\">",
"        19920895",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor FB and Russo J, &ldquo;Efficacy of Modafinil Compared to Dextroamphetamine for the Treatment of Attention Deficit Hyperactivity Disorder in Adults,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2000, 10(4):311-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1159/abstract-text/11191692/pubmed\" id=\"11191692\" target=\"_blank\">",
"        11191692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Modafinil in Narcolepsy Multicenter Study Group, &ldquo;Randomized Trial of Modafinil for the Treatment of Pathological Somnolence in Narcolepsy,&rdquo;",
"      <i>",
"       Ann Neurol",
"      </i>",
"      , 1998, 43(1):88-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1159/abstract-text/9450772/pubmed\" id=\"9450772\" target=\"_blank\">",
"        9450772",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson CH, et al,  &ldquo;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs. A Scientific Statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117:2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1159/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wong, YN, &ldquo;Single-Dose Pharmacokinetics of Modafinil and Methylphenidate Given Alone or in Combination in Healthy Male Volunteers,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1998, 38(3):276-282.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1159/abstract-text/9549666/pubmed\" id=\"9549666\" target=\"_blank\">",
"        9549666",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10157 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_8_1159=[""].join("\n");
var outline_f1_8_1159=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197665\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197666\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197693\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197669\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197670\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197671\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197672\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197647\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16564662\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197632\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197695\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961086\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11305814\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197648\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197690\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197691\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197651\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197636\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197688\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197641\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197661\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197642\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197654\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197674\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197653\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197644\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197655\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197635\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197650\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10157\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10157|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/26/28069?source=related_link\">",
"      Modafinil: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/20/38214?source=related_link\">",
"      Modafinil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_8_1160="Ampicillin and sulbactam: Drug information";
var content_f1_8_1160=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ampicillin and sulbactam: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/3/35891?source=see_link\">",
"    see \"Ampicillin and sulbactam: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/3/29750?source=see_link\">",
"    see \"Ampicillin and sulbactam: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Unasyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Unasyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F135112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Penicillin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F135094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Unasyn&reg; (ampicillin/sulbactam) is a combination product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Susceptible infections:",
"     </b>",
"     I.M., I.V.: 1000-2000 mg ampicillin (1500-3000 mg Unasyn&reg;) every 6 hours (maximum: 8 g ampicillin daily, 12 g Unasyn&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute bacterial rhinosinusitis, severe infection requiring hospitalization (unlabeled use):",
"     </b>",
"     I.V.: 1500-3000 mg every 6 hours for 5-7 days  (Chow, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Amnionitis, cholangitis, diverticulitis, endomyometritis (with doxycycline), endophthalmitis, epididymitis/orchitis, liver abscess (with metronidazole), or peritonitis:",
"     </b>",
"     I.V.: 3000 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bite (human, canine/feline):",
"     </b>",
"     <i>",
"      Pasteurella multocida :",
"     </i>",
"     I.V.: 1500-3000 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Endocarditis (unlabeled use) (Baddour, 2005):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Enterococcus organism (resistant to penicillin/susceptible to aminoglycoside and vancomycin):",
"     </i>",
"     I.V.: 3000 mg every 6 hours with concomitant gentamicin for 6 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     If enterococcus is gentamicin resistant, then &gt;6 weeks of ampicillin-sulbactam therapy needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     HACEK organism: I.V.: 3000 mg every 6 hours for 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Intravascular catheter-associated bloodstream infection,",
"      <i>",
"       Acinetobacter",
"      </i>",
"      spp (unlabeled use) (IDSA, 2009):",
"     </b>",
"     I.V.: 3000 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Orbital cellulitis:",
"     </b>",
"     I.V.: 3000 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Osteomyelitis (diabetic foot) (Lipsky, 2004):",
"     </b>",
"     I.V.: 3000 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pelvic inflammatory disease:",
"     </b>",
"     I.V.: 3000 mg every 6 hours with doxycycline",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Peritonitis associated with CAPD:",
"     </b>",
"     Intraperitoneal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Intermittent:",
"     </i>",
"     3000 mg added to one exchange every 12 hours; allow to dwell for at least 6 hours (Blackwell, 1990; Li, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Continuous:",
"     </i>",
"     Loading dose: 1500 mg per liter of dialysate; maintenance dose: 150 mg per liter of dialysate (Li, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pneumonia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Aspiration or community-acquired:",
"     </i>",
"     I.V.: 1500-3000 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Hospital-acquired:",
"     </i>",
"     I.V.: 3000 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Urinary tract infections, pyelonephritis:",
"     </b>",
"     I.V.: 3000 mg every 6 hours for 14 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F135104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/3/29750?source=see_link\">",
"      see \"Ampicillin and sulbactam: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Unasyn&reg; (ampicillin/sulbactam) is a combination product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Susceptible infections:",
"     </b>",
"     Children and Adolescents: I.V.: 100-400 mg ampicillin/kg/day divided every 6 hours (maximum: 8 g ampicillin daily, 12 g Unasyn&reg;).",
"     <b>",
"      Note:",
"     </b>",
"     The American Academy of Pediatrics recommends a dose of up to 300 mg ampicillin/kg/day for severe infection in infants &gt;1 month of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Endocarditis (unlabeled use) (Baddour, 2005):",
"     </b>",
"     <i>",
"      Enterococcus organism (resistant to penicillin/susceptible to aminoglycoside and vancomycin):",
"     </i>",
"     Infants, Children, and Adolescents: I.V.: 300 mg ampicillin/kg/day in 4 divided doses with concomitant gentamicin for 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Epiglottitis:",
"     </b>",
"     Children and Adolescents: I.V.: 100-200 mg ampicillin/kg/day divided in 4 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Intravascular catheter-associated bloodstream infection (unlabeled use) (IDSA, 2009):",
"     </b>",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants: I.V.: 100-150 mg ampicillin/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adolescents: I.V.: 100-200 mg ampicillin/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Mild-to-moderate infections:",
"     </b>",
"     Children and Adolescents: I.V.: 100-200 mg ampicillin/kg/day (150-300 mg Unasyn&reg;) divided every 6 hours (maximum: 8 g ampicillin daily, 12 g Unasyn&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Peritonsillar and retropharyngeal abscess:",
"     </b>",
"     Children and Adolescents: I.V.: 200 mg ampicillin/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Severe infections:",
"     </b>",
"     Children and Adolescents: I.V.: 200-400 mg ampicillin/kg/day divided every 6 hours (maximum: 8 g ampicillin daily, 12 g Unasyn&reg;)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F135095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F135096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Estimation of renal function for the purpose of drug dosing should be done using the Cockcroft-Gault formula.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-29 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 1500-3000 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     5-14 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 1500-3000 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): 1500-3000 mg  every 12-24 hours (Heintz, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times weekly, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis (PD): 3000 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug levels in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment (Heintz, 2009; Trotman, 2005):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVH: Initial: 3 g; maintenance: 1500-3000 mg every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVHD: Initial: 3 g; maintenance: 1500-3000 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVHDF: Initial: 3 g; maintenance: 1500-3000 mg every 6-8 hours",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F135070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1.5 g: Ampicillin 1 g and sulbactam 0.5 g; 3 g: Ampicillin 2 g and sulbactam 1 g; 15 g: Ampicillin 10 g and sulbactam 5 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Unasyn&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1.5 g: Ampicillin 1 g and sulbactam 0.5 g [contains sodium 115 mg (5 mEq)/1.5 g)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     3 g: Ampicillin 2 g and sulbactam 1 g [contains sodium 115 mg (5 mEq)/1.5 g)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     15 g: Ampicillin 10 g and sulbactam 5 g [bulk package; contains sodium 115 mg (5 mEq)/1.5 g)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F135054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F135074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer around-the-clock to promote less variation in peak and trough serum levels. Administer by slow injection over 10-15 minutes or I.V. over 15-30 minutes. Ampicillin and gentamicin should not be mixed in the same I.V. tubing.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Some penicillins (eg, ampicillin, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides",
"     <i>",
"      in vitro",
"     </i>",
"     . This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent Y-site administration should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F135118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, anidulafungin, aztreonam, bivalirudin, cefepime, dexmedetomidine, docetaxel, enalaprilat, etoposide phosphate, famotidine, fenoldopam, filgrastim, fluconazole, fludarabine, gallium, gemcitabine, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), insulin (regular), linezolid, meperidine, morphine, paclitaxel, palonosetron, pemetrexed, remifentanil, tacrolimus, teniposide, theophylline, thiotepa.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aminoglycosides (gentamicin, tobramycin), amiodarone, amphotericin B cholesteryl sulfate complex, ciprofloxacin, idarubicin, nicardipine, ondansetron.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cisatracurium, diltiazem, sargramostim, vancomycin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F135073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible bacterial infections involved with skin and skin structure, intra-abdominal infections, gynecological infections; spectrum is that of ampicillin plus organisms producing beta-lactamases such as",
"     <i>",
"      S. aureus",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Klebsiella",
"     </i>",
"     ,",
"     <i>",
"      Acinetobacter",
"     </i>",
"     ,",
"     <i>",
"      Enterobacter",
"     </i>",
"     , and anaerobes",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14470537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute bacterial rhinosinusitis (ABRS); endocarditis; intravascular catheter-associated bloodstream infection caused by susceptible bacteria; community-acquired pneumonia;  early-onset hospital-acquired pneumonia",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F135110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see Ampicillin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Local: Pain at injection site (I.M.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Pain at injection site (I.V.), thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction (may include serum sickness, urticaria, bronchospasm, hypotension, etc)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal distension, agranulocytosis, anemia. atypical lymphocytosis, candidiasis, chest pain, chills, dysuria, edema, eosinophilia, epistaxis, erythema, facial swelling, fatigue, flatulence, gastritis, glossitis, hairy tongue, headache, interstitial nephritis, itching, leukopenia, liver enzymes increased, malaise, mucosal bleeding, nausea, pseudomembranous colitis, seizure, stomatitis, substernal pain, throat tightness, thrombocytopenia, urine retention, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F135077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ampicillin, sulbactam, penicillins, or any component of the formulations",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F135058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rash: Appearance of a rash should be carefully evaluated to differentiate a nonallergic ampicillin rash from a hypersensitivity reaction; rash occurs in 5% to 10% of children and is a generalized dull red, maculopapular rash, generally appearing 3-14 days after the start of therapy. It normally begins on the trunk and spreads over most of the body. It may be most intense at pressure areas, elbows, and knees.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infectious mononucleosis: A high percentage of patients with infectious mononucleosis have developed rash during therapy; ampicillin-class antibiotics not recommended in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F135063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to Ampicillin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atenolol: Ampicillin may decrease the bioavailability of Atenolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: May decrease the serum concentration of Ampicillin. Management: Chloroquine prescribing information recommends separating administration of ampicillin and chloroquine by at least 2 hours to minimize any potential negative impact of chloroquine on ampicillin bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Ampicillin. Management: Administer oral ampicillin at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F135066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6028245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Both ampicillin and sulbactam cross the placenta. Maternal use of penicillins has generally not resulted in an increased risk of birth defects. When used during pregnancy, pharmacokinetic changes have been observed with ampicillin alone (refer to the Ampicillin monograph for details). Ampicillin/sulbactam may be considered for prophylactic use prior to cesarean delivery (consult current guidelines).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F135100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6028246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ampicillin and sulbactam are both excreted into breast milk in low concentrations. The manufacturer recommends that caution be used if administering to lactating women. Nondose-related effects could include modification of bowel flora and allergic sensitization of the infant. The maternal dose of sulbactam does not need altered in the postpartum period. Also refer to the Ampicillin monograph.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F135079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Ampicillin-Sulbactam Sodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 (1-0.5) g (1): $4.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 (2-1) g (1): $7.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 (10-5) g (1): $71.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Ampicillin-Sulbactam Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 (1-0.5) g (1): $4.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 (2-1) g (1): $6.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 (10-5) g (1): $39.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Unasyn Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 (1-0.5) g (1): $9.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 (2-1) g (1): $17.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 (10-5) g (1): $86.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Unasyn Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 (1-0.5) g (1): $10.57",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F135068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     With prolonged therapy, monitor hematologic, renal, and hepatic function; monitor for signs of anaphylaxis during first dose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ambacillin (TW);",
"     </li>",
"     <li>",
"      Ambacitam (TH);",
"     </li>",
"     <li>",
"      Ampibactan (VE);",
"     </li>",
"     <li>",
"      Ampimax (PH);",
"     </li>",
"     <li>",
"      Ampisulciillin (BG);",
"     </li>",
"     <li>",
"      Amsubac (TH);",
"     </li>",
"     <li>",
"      Ansutam (TW);",
"     </li>",
"     <li>",
"      Baccillin (KP);",
"     </li>",
"     <li>",
"      Bactacin (KP);",
"     </li>",
"     <li>",
"      Bactesyn (ID);",
"     </li>",
"     <li>",
"      Prixin (PY);",
"     </li>",
"     <li>",
"      Rukasyn (KP);",
"     </li>",
"     <li>",
"      Shinasyn (MY);",
"     </li>",
"     <li>",
"      Silgram (PH);",
"     </li>",
"     <li>",
"      Sulam (TH);",
"     </li>",
"     <li>",
"      Sulbaccin (TH);",
"     </li>",
"     <li>",
"      Sulbacin (IN, KP, PH);",
"     </li>",
"     <li>",
"      Sultacilin (PH);",
"     </li>",
"     <li>",
"      Sultamicilina (AR);",
"     </li>",
"     <li>",
"      Ubactam (KP);",
"     </li>",
"     <li>",
"      Ultramox (PH);",
"     </li>",
"     <li>",
"      Unacid (DE);",
"     </li>",
"     <li>",
"      Unacim (FR);",
"     </li>",
"     <li>",
"      Unasyn (AE, AT, BF, BH, BJ, BR, CI, CL, CN, CO, CR, CY, CZ, EC, EE, EG, ET, GH, GM, GN, GT, HK, HN, ID, IL, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NI, OM, PA, PE, PH, PL, QA, RU, SA, SC, SD, SG, SL, SN, SV, SY, TH, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Unasyna (AR, UY);",
"     </li>",
"     <li>",
"      Xilbac (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F135057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. The addition of sulbactam, a beta-lactamase inhibitor, to ampicillin extends the spectrum of ampicillin to include some beta-lactamase-producing organisms.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F135076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ampicillin:",
"     </b>",
"     See Ampicillin monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sulbactam:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Distribution: Widely distributed to bile, blister, and tissue fluids; distributed to cerebrospinal fluid in the presence of inflamed meninges",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protein binding: 38%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life elimination: Normal renal function: 1-1.3 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Elimination kinetics of both ampicillin and sulbactam are similarly affected in patients with renal impairment, therefore, the blood concentration ratio is expected to remain constant regardless of renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excretion: Urine (~75% to 85% as unchanged drug) within 8 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baddour LM, Wilson WR, Bayer AS, et al, &ldquo;Infective Endocarditis. Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association - Executive Summary:",
"      <i>",
"       Endorsed by the Infectious Diseases Society of America",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(23):3167-184.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/15956145/pubmed\" id=\"15956145\" target=\"_blank\">",
"        15956145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blackwell BG, Leggett JE, Johnson CA, et al, &ldquo;Ampicillin and Sulbactam Pharmacokinetics and Pharmacodynamics in Continuous Ambulatory Peritoneal Dialysis (CAPD),&rdquo;",
"      <i>",
"       Perit Dial Int",
"      </i>",
"      , 1990, 10(3):221-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/2099158/pubmed\" id=\"2099158\" target=\"_blank\">",
"        2099158",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blum RA, Kohli RK, Harrison NJ, et al, &ldquo;Pharmacokinetics of Ampicillin (2.0 Grams) and Sulbactam (1.0 Gram) Coadministered to Subjects With Normal and Abnormal Renal Function and With End-Stage Renal Disease on Hemodialysis,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1989, 33(9):1470-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/2817847 /pubmed\" id=\"2817847 \" target=\"_blank\">",
"        2817847",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2013, 70(3):195-283.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/23327981/pubmed\" id=\"23327981\" target=\"_blank\">",
"        23327981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(8):e72-112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/22438350/pubmed\" id=\"22438350\" target=\"_blank\">",
"        22438350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow MS, Quintiliani R, and Nightingale CH, &ldquo;",
"      <i>",
"       In Vivo",
"      </i>",
"      Inactivation of Tobramycin by Ticarcillin. A Case Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1982, 247(5):658-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/6798229/pubmed\" id=\"6798229\" target=\"_blank\">",
"        6798229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dajani AS, &ldquo;Sulbactam/Ampicillin in Pediatric Infections,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1988, 35(Suppl 7):35-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daly JS, Dodge RA, Glew RH, et al, &ldquo;Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages,\"",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 1997, 17(1):42-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/9069064/pubmed\" id=\"9069064\" target=\"_blank\">",
"        9069064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 318(7):419-26 and 318(8):490-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/3277054/pubmed\" id=\"3277054\" target=\"_blank\">",
"        3277054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dowell JA, Korth-Bradley J, Milisci M, et al, &ldquo;Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2001, 41:979-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/11549103/pubmed\" id=\"11549103\" target=\"_blank\">",
"        11549103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farchione LA, &ldquo;Inactivation of Aminoglycosides by Penicillins,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1982, 8(Suppl A):27-36.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuchs PC, Stickel S, Anderson PH, et al, &ldquo;",
"      <i>",
"       In Vitro",
"      </i>",
"      Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(1):182-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/2014975/pubmed\" id=\"2014975\" target=\"_blank\">",
"        2014975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldfarb J, Aronoff SC, Jaff&eacute; A, et al, &ldquo;Sultamicillin in the Treatment of Superficial Skin and Soft Tissue Infections in Children,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1987, 31(4):663-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/3038003/pubmed\" id=\"3038003\" target=\"_blank\">",
"        3038003",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Halstenson CE, Wong MO, Herman CS, et al, &ldquo;Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1992, 36(9):1832-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/1416875/pubmed\" id=\"1416875\" target=\"_blank\">",
"        1416875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hitt CM, Patel KB, Nicolau DP, et al, &ldquo;Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(23):2704-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/9408514/pubmed\" id=\"9408514\" target=\"_blank\">",
"        9408514",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Itokazu GS and Danziger LH, &ldquo;Ampicillin-Sulbactam and Ticarcillin-Clavulanic Acid: A Comparison of Their",
"      <i>",
"       In Vitro",
"      </i>",
"      Activity and Review of Their Clinical Efficacy,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1991, 11(5):382-414.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/1745624/pubmed\" id=\"1745624\" target=\"_blank\">",
"        1745624",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Konishi H, Goto M, Nakamoto Y, et al, &ldquo;Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1983, 23(5):653-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/6223576/pubmed\" id=\"6223576\" target=\"_blank\">",
"        6223576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kulhanjian J, Dunphy MG, Hamstra S, et al, &ldquo;Randomized Comparative Study of Ampicillin/Sulbactam vs Ceftriaxone for Treatment of Soft Tissue and Skeletal Infections in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1989, 8(9):605-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/2677956/pubmed\" id=\"2677956\" target=\"_blank\">",
"        2677956",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lau A, Lee M, Flascha S, et al, &ldquo;Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients With Normal Renal Function,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1983, 24(4):533-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/6651279/pubmed\" id=\"6651279\" target=\"_blank\">",
"        6651279",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li PK, Szeto CC, Piraino B, et al, \"Peritoneal Dialysis-Related Infections Recommendations: 2010 Update,\"",
"      <i>",
"       Perit Dial Int",
"      </i>",
"      , 2010, 30(4):393-423",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/20628102/pubmed\" id=\"20628102\" target=\"_blank\">",
"        20628102",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky BA, Berendt AR, Cornia PB, et al, \"2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(12):e132-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/22619242/pubmed\" id=\"22619242\" target=\"_blank\">",
"        22619242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mermel LA, Allon M, Bouza E, et al, &ldquo;Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 49(1):1-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/19489710/pubmed\" id=\"19489710\" target=\"_blank\">",
"        19489710",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meyers BR, Wilkinson P, Mendelson MH, et al, &ldquo;Pharmacokinetics of Ampicillin-Sulbactam in Healthy Elderly and Young Volunteers,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(10):2098-101.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/1759832/pubmed\" id=\"1759832\" target=\"_blank\">",
"        1759832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oehler RL, Velez AP, Mizrachi M, et al, &ldquo;Bite-Related and Septic Syndromes Caused by Cats and Dogs,&rdquo;",
"      <i>",
"       Lancet Inf Dis",
"      </i>",
"      ,  2009, 9(7):439-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/19555903/pubmed\" id=\"19555903\" target=\"_blank\">",
"        19555903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rafailidis PI, Ioannidou EN, and Falagas ME, &ldquo;Ampicillin/Sulbactam: Current Status in Severe Bacterial Infections,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2007, 67(13):1829-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/17722953/pubmed\" id=\"17722953\" target=\"_blank\">",
"        17722953",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rho SP, Jones A, Woo M, et al, &ldquo;Single Dose Pharmacokinetics of Intravenous Ampicillin Plus Sulbactam in Healthy Elderly and Young Subjects,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1989, 24(4):573-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/2613605/pubmed\" id=\"2613605\" target=\"_blank\">",
"        2613605",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Russoe ME and Atkins-Thor E, &ldquo;Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate,\"",
"      <i>",
"       Clin Nephrol",
"      </i>",
"      , 1981, 15(4):175-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/7237864/pubmed\" id=\"7237864\" target=\"_blank\">",
"        7237864",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DL, Bisno AL, Chambers HF, et al, &ldquo;Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005; 41(10):1373&ndash;406.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/16231249/pubmed\" id=\"16231249\" target=\"_blank\">",
"        16231249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Syriopoulou V, Bitsi M, Theodoridis C, et al, &ldquo;Clinical Efficacy of Sulbactam/Ampicillin in Pediatric Infections Caused by Ampicillin-Resistant or Penicillin-Resistant Organisms,&rdquo;",
"      <i>",
"       Rev Infect Dis",
"      </i>",
"      , 1986, 8(Suppl 5):630-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thompson MIB, Russo ME, Saxon BJ, et al, &ldquo;Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1982, 21(2):268-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/6462107/pubmed\" id=\"6462107\" target=\"_blank\">",
"        6462107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Viollier AF, Standiford HC, Drusano GL, et al, &ldquo;Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin, and Piperacillin, With and Without Gentamicin,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1985, 15(5):597-606.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/4008387/pubmed\" id=\"4008387\" target=\"_blank\">",
"        4008387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wald E, Reilly JS, Bluestone CD, et al, &ldquo;Sulbactam/Ampicillin in the Treatment of Acute Epiglottitis in Children,&rdquo;",
"      <i>",
"       Rev Infect Dis",
"      </i>",
"      , 1986, 8(Suppl 5):617-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/3026014/pubmed\" id=\"3026014\" target=\"_blank\">",
"        3026014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walterspiel JN, Feldman S, Van R, et al, &ldquo;Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(9):1875-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/1952861/pubmed\" id=\"1952861\" target=\"_blank\">",
"        1952861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wright AJ, &ldquo;The Penicillins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(3):290-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/10090000/pubmed\" id=\"10090000\" target=\"_blank\">",
"        10090000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL and Bergman SA, &ldquo;Antibiotics and Their Use in the Treatment of Orofacial Infections, Part I and Part II,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1994, 42(5):398-402, 498-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/8/1160/abstract-text/7489869/pubmed\" id=\"7489869\" target=\"_blank\">",
"        7489869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8745 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_8_1160=[""].join("\n");
var outline_f1_8_1160=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135090\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135091\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135112\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135094\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135104\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135095\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135096\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673183\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135070\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135054\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135074\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135118\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135073\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14470537\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135110\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135077\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135058\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298749\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135063\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135066\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6028245\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135100\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6028246\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135079\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322990\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135068\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038527\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135057\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135076\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8745\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8745|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/3/35891?source=related_link\">",
"      Ampicillin and sulbactam: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/3/29750?source=related_link\">",
"      Ampicillin and sulbactam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_8_1161="Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus";
var content_f1_8_1161=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/8/1161/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/8/1161/contributors\">",
"     Stuart J Spechler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/8/1161/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/8/1161/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/8/1161/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/8/1161/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/8/1161/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barrett's esophagus is the condition in which any extent of metaplastic columnar epithelium that predisposes to cancer development replaces the stratified squamous epithelium that normally lines the distal esophagus. The condition develops as a consequence of chronic gastroesophageal reflux disease (GERD), and predisposes to the development of adenocarcinoma of the esophagus.",
"   </p>",
"   <p>",
"    The issues related to the clinical manifestations and diagnosis of Barrett's esophagus will be reviewed here. The pathogenesis, malignant transformation, and management of this disorder, including surveillance for adenocarcinoma, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/12/8391?source=see_link\">",
"     \"Pathogenesis of Barrett's esophagus and its malignant transformation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barrett's esophagus is usually discovered during endoscopic examinations of middle-aged and older adults whose mean age at the time of diagnosis is approximately 55 years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/1\">",
"     1",
"    </a>",
"    ]. Although Barrett's esophagus can affect children, it rarely occurs before the age of five [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/2\">",
"     2",
"    </a>",
"    ]. This observation supports the contention that Barrett's esophagus is an acquired condition, not a congenital one.",
"   </p>",
"   <p>",
"    Barrett's esophagus appears to be uncommon in blacks and Asians. Data on the prevalence in Hispanics are contradictory, with some studies showing a similar prevalence to that in Caucasians [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/3\">",
"     3",
"    </a>",
"    ], and others showing a lesser prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The male to female ratio is approximately 2:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear if the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or nonsteroidal antiinflammatory drugs (NSAIDs), by inhibition of COX-2 expression, is associated with a decrease in the risk of Barrett&rsquo;s esophagus. In a single institution case-controlled study of 434 patients, current aspirin but not NSAID use was associated with a decreased risk of Barrett&rsquo;s esophagus (OR 0.56, 95% CI 0.39-0.80) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/7\">",
"     7",
"    </a>",
"    ]. However, a large-population based, case-controlled study failed to demonstrate an association with aspirin use and Barrett&rsquo;s esophagus; and the use of non-aspirin NSAIDs was associated with only a small decrease in risk of Barrett&rsquo;s esophagus (OR 0.69, 95% CI 0.49-0.97) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimates of the prevalence of Barrett's esophagus in the general population have varied widely ranging from 0.4 to more than 20 percent depending in part upon the population studied and the definitions used [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. The following studies illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study from Sweden estimated that Barrett's esophagus was present in 1.6 percent of the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/14\">",
"       14",
"      </a>",
"      ]. Applying these prevalence estimates to the United States would translate into about 3.3 million individuals with Barrett's esophagus [",
"      <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/15\">",
"       15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      An important additional observation from this report was that 44 percent of patients lacked \"troublesome heartburn",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      acid regurgitation during the past three months\" suggesting that screening programs based upon reflux symptoms alone may be inadequate to identify patients with Barrett's esophagus.",
"     </li>",
"     <li>",
"      In a study conducted in the United States, the prevalence of Barrett's esophagus was 6.8 percent among 961 patients undergoing a colonoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/16\">",
"       16",
"      </a>",
"      ]. Among 556 patients who had never had heartburn, the prevalence was 5.6 percent. Among 384 subjects with a history of heartburn, the prevalence was 8.3 percent. Most cases were \"short-segment\". Long-segment Barrett's was uncommon in those without a history of heartburn. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Differences between long- and short-segment Barrett's'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Among patients who have endoscopic examinations because of chronic gastroesophageal reflux disease (GERD) symptoms, long-segment Barrett's esophagus can be found in 3 to 5 percent, whereas 10 to 15 percent have short-segment Barrett's esophagus (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Differences between long- and short-segment Barrett's'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Familial aggregation of Barrett's esophagus has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/19\">",
"     19",
"    </a>",
"    ]. It is unclear if this is due to common environmental exposures",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an inherited predisposition. Germline mutations in the MSR1, ASCC1, and CTHRC1 genes have been associated with the presence of Barrett's esophagus and esophageal adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/20\">",
"     20",
"    </a>",
"    ]. However, large cohort studies are needed to validate these findings.",
"   </p>",
"   <p>",
"    The sensitivity of endoscopy for detection of Barrett's is related to the length of involved mucosa, with detection being more likely in patients who have long-segment Barrett's (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Differences between long- and short-segment Barrett's'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/21\">",
"     21",
"    </a>",
"    ]. The overall reliability of endoscopy with biopsy for detection of specialized intestinal metaplasia in Barrett's esophagus is approximately 80 percent. This was illustrated in a study that included 116 patients who were involved in a Veterans Administration Cooperative Study that required two endoscopies six weeks apart [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/22\">",
"     22",
"    </a>",
"    ]. Barrett's esophagus was confirmed by biopsy in only one of the two endoscopies in 20 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H623517391\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specialized intestinal columnar metaplasia typical of Barrett's esophagus causes no symptoms. Most patients are seen initially for symptoms of associated gastroesophageal reflux disease (GERD), such as heartburn, regurgitation, and dysphagia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GERD associated with long-segment Barrett's esophagus frequently is complicated by esophageal ulceration, stricture, and hemorrhage (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59145 \" href=\"UTD.htm?25/3/25662\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75133 \" href=\"UTD.htm?22/31/23024\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/1\">",
"     1",
"    </a>",
"    ]. In patients with symptomatic GERD, erosive esophagitis is an independent risk factor for Barrett&rsquo;s esophagus, conferring a fivefold increased risk of Barrett&rsquo;s at five-year follow-up (relative risk ratio [RRR] 5.2; 95% CI 1.2-22.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/23\">",
"     23",
"    </a>",
"    ]. Some studies have suggested that patients with a peptic stricture have a higher prevalence of Barrett's esophagus than those without strictures. This relationship is not surprising since both peptic stricture and Barrett's esophagus are associated with more severe GERD. However, this association has been challenged in a study of patients referred for endoscopy for GERD in whom the prevalence of intestinal metaplasia was the same in patients with and without strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CANCER INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of cancer arising in Barrett's esophagus is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of Barrett's esophagus\", section on 'Influence of Barrett's esophagus on mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic examination generally is required to diagnose Barrett's esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/18\">",
"     18",
"    </a>",
"    ]. Two criteria must be fulfilled:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The endoscopist must document that columnar epithelium lines the distal esophagus.",
"     </li>",
"     <li>",
"      Histologic examination of biopsy specimens from that columnar epithelium must reveal intestinal metaplasia. Some data suggest that gastric cardia-type epithelium in the esophagus also might predispose to cancer and thus might be considered \"Barrett's esophagus,\" but most authorities still require the presence of intestinal metaplasia for an unequivocal diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To document that columnar epithelium lines the esophagus, the endoscopist must identify both the squamocolumnar and gastroesophageal junctions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/27\">",
"     27",
"    </a>",
"    ]. Columnar epithelium has a reddish color and velvet-like texture on endoscopic examination, whereas squamous epithelium has a pale, glossy appearance (",
"    <a class=\"graphic graphic_picture graphicRef69873 \" href=\"UTD.htm?43/32/44557\">",
"     picture 2",
"    </a>",
"    ). The juxtaposition of these epithelia at the squamocolumnar junction forms a visible line called the Z-line.",
"   </p>",
"   <p>",
"    In contrast, the gastroesophageal junction is the imaginary line at which the esophagus ends and the stomach begins anatomically. The gastroesophageal junction can be defined as the level of the most proximal extent of the gastric folds [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the squamocolumnar and gastroesophageal junctions coincide (",
"    <a class=\"graphic graphic_figure graphicRef82421 \" href=\"UTD.htm?4/49/4895\">",
"     figure 1",
"    </a>",
"    ), the entire esophagus is lined by squamous epithelium. When the squamocolumnar junction is located proximal to the gastroesophageal junction (GEJ) (",
"    <a class=\"graphic graphic_figure graphicRef76055 \" href=\"UTD.htm?10/63/11263\">",
"     figure 2",
"    </a>",
"    ), there is a columnar-lined segment of esophagus. If biopsy specimens from that segment show specialized intestinal metaplasia, then the patient has Barrett's esophagus. The condition is called long-segment Barrett's esophagus when the distance between the Z-line and the GEJ is &ge;3 cm, and short-segment Barrett's esophagus when that distance is &lt;3 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/28\">",
"     28",
"    </a>",
"    ]. If the Z-line and the GEJ coincide and biopsy specimens at the Z-line show intestinal metaplasia, the condition is called intestinal metaplasia at the GEJ [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these diagnostic criteria are widely accepted, they are not ideal. There can be significant interobserver variability in defining the length of Barrett's esophagus, which may in part be caused by the variable configuration that Barrett's esophagus can have and the presence of a hiatus hernia (",
"    <a class=\"graphic graphic_figure graphicRef59429 \" href=\"UTD.htm?35/20/36162\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/30\">",
"     30",
"    </a>",
"    ]. Furthermore, intestinal metaplasia may not always be apparent on endoscopy. In one study, the positive predictive value of endoscopy for the presence of intestinal metaplasia was only 34 percent; correct diagnosis was more likely in patients with long-segment Barrett's esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some Asian countries (particularly Japan) the GEJ is defined as the distal end of the lower esophageal palisade vessels (rather than the upper end of the gastric longitudinal folds). However, one study found that using the palisade vessels had lower interobserver reliability (kappa coefficient of only 0.14) than using the gastric folds as a landmark (kappa coefficient of 0.35) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/31\">",
"     31",
"    </a>",
"    ]. The low interobserver reliability of both approaches underscores the difficulty in achieving an optimal method of assessing the length of Barrett's esophagus.",
"   </p>",
"   <p>",
"    An endoscopic grading system (The Prague C &amp; M Criteria) has been recommended for assessing the presence and extent of Barrett's esophagus (",
"    <a class=\"external\" href=\"file://iwgco.com/e107_plugins/content/content.php?content.18\">",
"     file://iwgco.com/e107_plugins/content/content.php?content.18",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/26,32\">",
"     26,32",
"    </a>",
"    ]. The criteria are based upon assessment of the circumferential extent (the C value) and maximum extent (the M value) of metaplastic epithelium above the GEJ (C value = Depth of endoscope insertion from the circumferential extent of suspected columnar epithelium - Depth of endoscope insertion at the GE junction; M value= Depth of endoscope insertion from the maximal extent of columnar epithelium - Depth of endoscope insertion at the GE junction). A validation study found that the criteria had good interobserver reliability for Barrett's esophagus &ge;1 cm in length. Whether these criteria will become adopted broadly remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intestinal metaplasia at the GEJ and in the gastric cardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional teaching holds that the normal Z-line is a junction between esophageal squamous epithelium and gastric cardia-type epithelium, a columnar lining characterized by tortuous, tubular glands comprised of mucus-secreting cells and devoid of acid-secreting parietal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. It was previously believed that cardia-type epithelium can line up to 2 cm of the most distal esophagus, and may extend several centimeters below the GEJ to line the most proximal stomach (the gastric cardia) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/30,33\">",
"     30,33",
"    </a>",
"    ]. However, more recent data indicate that this traditional teaching is incorrect, and that cardia-type epithelium usually extends only 1 or 2 mm beyond the Z-line. Furthermore, some authorities now contend that the normal Z-line is a junction between esophageal squamous and gastric fundic (oxyntic) epithelia, and that cardia-type epithelium is an abnormal, metaplastic mucosa acquired as a consequence of chronic inflammation in the distal esophagus caused by gastroesophageal reflux disease (GERD) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of 40 patients who had subtotal esophagectomy with esophagogastrostomy, an operation frequently complicated by severe reflux esophagitis in the esophageal remnant, supports the notion that cardia-type epithelium is metaplastic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/36\">",
"     36",
"    </a>",
"    ]. Endoscopic examinations performed at a median of 36 months postoperatively showed that 19 of the 40 patients had developed columnar metaplasia in the esophageal remnant (10 cardia-type epithelium, 9 intestinal metaplasia). Seven patients who had serial endoscopic examinations showed progression from cardia-type epithelium on the initial postoperative endoscopy to specialized intestinal metaplasia on subsequent studies. The median time to the development of cardia-type epithelium was 14 months, whereas specialized intestinal metaplasia was found at a median of 27 months postoperatively. These findings suggest that cardiac epithelium is not only metaplastic, but also the precursor of intestinal metaplasia in the esophagus.",
"   </p>",
"   <p>",
"    Intestinal metaplasia can develop in the stomach as a consequence of chronic H. pylori gastritis. Histologically, intestinal metaplasia in the stomach can be indistinguishable from intestinal metaplasia in the esophagus. Since the GEJ cannot be identified with great precision, it can be difficult to determine whether short segments of intestinal metaplasia found in the GEJ region are lining the esophagus (short-segment Barrett's esophagus) or the proximal stomach (intestinal metaplasia of the gastric cardia). As discussed above, the term \"intestinal metaplasia at the GEJ\" is used to describe the condition in which intestinal metaplasia is found at a Z-line that appears to coincide precisely with the GEJ. Rather than constituting an independent condition, intestinal metaplasia at the GEJ almost certainly represents either short-segment Barrett's esophagus or intestinal metaplasia of the gastric cardia. These conditions cannot be distinguished reliably because the morphological and histochemical features of gastric and esophageal intestinal metaplasia are similar, and because the gross landmarks used to identify the GEJ do not have the precision necessary to localize a mucosa whose extent may be measured in only millimeters.",
"   </p>",
"   <p>",
"    Circumstantial evidence suggests that the risk of malignancy is substantially higher for intestinal metaplasia in the esophagus than for that in the stomach. As an example, one study found that both the prevalence and incidence of dysplasia (the precursor of malignancy) were significantly higher in patients with short-segment Barrett's esophagus than in those with intestinal metaplasia of the gastric cardia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/37\">",
"     37",
"    </a>",
"    ]. However, in a population-based cohort study, subjects with intestinal metaplasia of the GEJ appeared to have substantially lower rates of progression to esophageal adenocarcinoma than those with Barrett's esophagus (0 percent compared to 7 percent at 10 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medical societies recommend endoscopic cancer surveillance routinely for patients with Barrett's esophagus, but not for patients with intestinal metaplasia in the stomach. As a result, the distinction between these two conditions has important clinical implications. A number of markers have been proposed to differentiate intestinal metaplasia of the cardia from short-segment Barrett's esophagus such as the pattern of cytokeratin staining and the presence of colonic-type sulfomucins. However, the utility of biomarkers in distinguishing short-segment Barrett's esophagus from intestinal metaplasia of the gastric cardia has not been established and, for now, clinical decisions should not be based on the presence of these biomarkers. For patients found to have intestinal metaplasia at the GEJ, a conservative management approach is to assume a worst-case scenario in which the condition is considered to represent short-segment Barrett's esophagus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differences between long- and short-segment Barrett's",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the prevalence of short-segment Barrett's esophagus is substantially higher than long-segment Barrett's esophagus. Both conditions are diagnosed most frequently in patients age 55 years and older, and are predominantly seen in male Caucasians.",
"   </p>",
"   <p>",
"    These observations were illustrated in a study that included 889 patients undergoing upper endoscopy who had protocol biopsies obtained at the esophagogastric junction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/9\">",
"     9",
"    </a>",
"    ]. The overall prevalence of specialized intestinal metaplasia was 13.2 percent with the following distribution:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Long-segment &ndash; 1.6 percent",
"     </li>",
"     <li>",
"      Short-segment &ndash; 6.4 percent",
"     </li>",
"     <li>",
"      Intestinal metaplasia at the GEJ &ndash; 5.6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with long and short-segment Barrett's were predominantly male and white. Patients with short-segment Barrett's had a shorter history of heartburn and many had no GERD symptoms at all. In contrast, those with intestinal metaplasia of the GEJ had a similar gender distribution and were more likely to be infected by Helicobacter pylori.",
"   </p>",
"   <p>",
"    The degree and mechanism of acid exposure in patients with short- and long-segment Barrett's esophagus suggest that patients who develop long-segment Barrett's were predisposed to more severe reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with long-segment Barrett's tend to have upright and supine reflux in contrast to those with short-segment Barrett's who have predominantly upright reflux",
"     </li>",
"     <li>",
"      Proximal esophageal acid exposure is more common in patients with long-segment Barrett's",
"     </li>",
"     <li>",
"      Compared with patients with long-segment Barrett's, those with short-segments tend to have higher LES pressures and increased distal esophageal peristaltic amplitudes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dysplasia and adenocarcinoma in short-segment Barrett's",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of dysplasia and adenocarcinoma in patients with short-segment Barrett's esophagus is being clarified. It appears that patients with short-segment Barrett's have a lower incidence of dysplasia since less mucosa is involved (6 to 8 versus 15 to 24 percent in long-segment Barrett's) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/9,40,41\">",
"     9,40,41",
"    </a>",
"    ]. Similarly, the risk of adenocarcinoma has been estimated to be 2 to 15 times higher in patients with long-segment Barrett's. The following three studies illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the prevalence and incidence of dysplasia and adenocarcinoma were compared between 78 patients with long-segment and 74 patients with short-segment Barrett's esophagus [",
"      <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/41\">",
"       41",
"      </a>",
"      ]. At diagnosis, the prevalence of dysplasia was significantly higher in those with long-segment (24 versus 8 percent). Adenocarcinoma was detected only in patients with long-segment Barrett's. During follow-up ranging from 12 to 40 months, dysplasia developed significantly more often in patients with long-segment Barrett's (8 versus 4 percent). No patients with short-segment Barrett's developed high grade esophageal dysplasia or adenocarcinoma.",
"     </li>",
"     <li>",
"      In another report that included 94 patients with intestinal metaplasia discovered during endoscopy, dysplasia or cancer were significantly more common in those with long-segment Barrett's compared with short-segment Barrett's or intestinal metaplasia of the esophagogastric junction (31, 10, and 6 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third study included 309 patients with Barrett's esophagus who were followed for an average of 3.8 years [",
"      <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/42\">",
"       42",
"      </a>",
"      ]. A nonsignificant trend toward an increased risk of adenocarcinoma was observed with longer lengths of Barrett's; a 5 cm difference in segment length was associated with a 1.7-fold increased cancer risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these retrospective data suggest that the risk of cancer for patients with short-segment Barrett's esophagus is less than that for patients with long-segment disease, there is yet no proof for this contention. As a result, patients with short- and long-segment Barrett's esophagus presently are managed similarly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SCREENING PATIENTS FOR BARRETT'S ESOPHAGUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;To decrease mortality from esophageal adenocarcinoma, it has been proposed that patients with gastroesophageal reflux disease (GERD) symptoms should be screened endoscopically for Barrett's esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. We suggest that patients with at least weekly GERD symptoms that have been present for at least five years and who have multiple risk factors for esophageal adenocarcinoma undergo screening for Barrett's esophagus. We propose that screening should not be performed in men younger than 50 years or in women of any age, regardless of the frequency of GERD symptoms, due to the very low incidence of esophageal adenocarcinoma in these groups.",
"   </p>",
"   <p>",
"    However, it is not clear that screening patients with GERD symptoms reliably identifies individuals at high risk for esophageal adenocarcinoma or has an impact on mortality. Long-segment Barrett's esophagus can be found in 3 to 5 percent of patients who have endoscopy for chronic GERD symptoms, whereas 10 to 15 percent have short-segment Barrett's esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/18\">",
"     18",
"    </a>",
"    ]. Studies have also shown that patients with GERD symptoms are at increased risk for esophageal adenocarcinoma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of five case-control studies with 1189 patients with esophageal adenocarcinoma and 4666 controls found that patients with weekly GERD symptoms were more likely than patients with less frequent symptoms or without symptoms to develop esophageal adenocarcinoma (odds ratio 4.9) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/45\">",
"       45",
"      </a>",
"      ]. The odds of developing esophageal adenocarcinoma were even higher in patients with daily symptoms (OR 7.4).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, whether to screen patients with GERD symptoms not only needs to take into account the relative risk of developing esophageal adenocarcinoma, but also the absolute risk. The impact of the incidence of esophageal adenocarcinoma on screening was evaluated using a Markov model based upon age- and sex-specific incidences of esophageal adenocarcinoma in American non-Hispanic whites with GERD symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/46\">",
"     46",
"    </a>",
"    ]. The study noted that the overall incidence of esophageal adenocarcinoma is low, but increases with age:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men between the ages of 30 and 80 years, the incidence ranged from 0.1 to",
"      <span class=\"nowrap\">",
"       15.4/100,000",
"      </span>",
"      for those without GERD or with GERD less than once per week, and from 0.4 to",
"      <span class=\"nowrap\">",
"       75.9/100,000",
"      </span>",
"      for those with GERD at least once per week.",
"     </li>",
"     <li>",
"      For women between the ages of 30 and 80 years, the rates were lower, ranging from 0 to",
"      <span class=\"nowrap\">",
"       2.3/100,000",
"      </span>",
"      for those without GERD or with GERD less than once per week, and from 0 to",
"      <span class=\"nowrap\">",
"       11.2/100,000",
"      </span>",
"      for those with GERD at least once per week.",
"     </li>",
"     <li>",
"      Of note, the incidence of esophageal adenocarcinoma for men without GERD was higher than the incidence for women with GERD at any given age (eg, at age 60 years the incidence in men without GERD was",
"      <span class=\"nowrap\">",
"       7.0/100,000",
"      </span>",
"      and the incidence in women with GERD was",
"      <span class=\"nowrap\">",
"       3.9/100,000).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another limitation of screening patients with GERD symptoms for Barrett's esophagus and esophageal adenocarcinoma is that more than 40 percent of patients with esophageal adenocarcinoma have no history of heartburn [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/45,47\">",
"     45,47",
"    </a>",
"    ]. Thus, any screening program that targets only patients with heartburn can have only limited impact on cancer mortality rates and there is little evidence that these programs have prevented deaths from esophageal adenocarcinoma. In published series of patients found to have these tumors, fewer than 5 percent were known to have had Barrett's esophagus before they presented with symptoms of esophageal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is also not clear that patients who are known to have Barrett's esophagus benefit from surveillance and, once the diagnosis of Barrett's esophagus has been established, patients are subject to the worry about the diagnosis, the inconvenience and risk associated with surveillance and, potentially, a financial burden from an increase in life insurance premiums [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3718356\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple societies have issued guidelines regarding screening patients for Barrett's esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/26,44,50,51\">",
"     26,44,50,51",
"    </a>",
"    ]. It is important to appreciate that these recommendations represent the opinions of committees, that the recommendations of different societies vary, and that none of these approaches has been proven effective in clinical studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13951529\">",
"    <span class=\"h3\">",
"     American Gastroenterological Association",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Gastroenterological Association (AGA) recommends screening patients with multiple risk factors associated with esophageal adenocarcinoma for Barrett's esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/26\">",
"     26",
"    </a>",
"    ]. Risk factors considered by the AGA include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age 50 years or older",
"     </li>",
"     <li>",
"      Male sex",
"     </li>",
"     <li>",
"      White race",
"     </li>",
"     <li>",
"      Chronic GERD",
"     </li>",
"     <li>",
"      Hiatal hernia",
"     </li>",
"     <li>",
"      Elevated body mass index",
"     </li>",
"     <li>",
"      Intra-abdominal distribution of body fat",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The AGA recommends against screening the general population with GERD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13951522\">",
"    <span class=\"h3\">",
"     American College of Gastroenterology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Practice Parameters Committee of the American College of Gastroenterology has recommended the following guideline on initial evaluation for patients with GERD [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"If the patient's history is typical for uncomplicated GERD, an initial trial of empirical therapy [including lifestyle modification (see below)] is appropriate. Patients in whom empiric therapy is unsuccessful or who have symptoms suggesting complicated disease should have further diagnostic testing [ie, endoscopy].\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms that might suggest complicated disease requiring early endoscopic evaluation include anorexia, weight loss, dysphagia, odynophagia, bleeding, and signs of systemic illness. In another publication dealing specifically with Barrett's esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/52\">",
"     52",
"    </a>",
"    ], the Practice Parameters Committee recommends that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Patients with chronic GERD symptoms are those most likely to have Barrett's esophagus and should undergo upper endoscopy.\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H257927204\">",
"    <span class=\"h3\">",
"     American College of Physicians",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Clinical Guidelines Committee of the American College of Physicians suggests that upper endoscopy may be indicated for screening for Barrett&rsquo;s esophagus in men older than 50 years with GERD symptoms for more than five years and the following additional risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nocturnal reflux symptoms",
"     </li>",
"     <li>",
"      Hiatus hernia",
"     </li>",
"     <li>",
"      Elevated body mass index",
"     </li>",
"     <li>",
"      Tobacco use",
"     </li>",
"     <li>",
"      Intra-abdominal distribution of fat",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3718363\">",
"    <span class=\"h2\">",
"     Alternate screening methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonendoscopic methods for screening are also being studied. One method uses a device called a capsule sponge (Cytosponge, Surepath; BD Diagnostics, Durham, NC) combined with an immunohistochemical biomarker (trefoil factor 3) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/53\">",
"     53",
"    </a>",
"    ]. The patient ingests a gelatin capsule that is attached to a string and contains a compressed mesh. The mesh is exposed when the gelatin capsule dissolves in the stomach. The mesh is then withdrawn through the esophagus where it obtains samples of the cells lining the esophageal lumen. The biomarker is then used to differentiate Barrett's epithelial cells from gastric cardia and squamous cells.",
"   </p>",
"   <p>",
"    In a study of 504 patients who had used acid suppressing therapy for more than three months during the preceding five years, 501 (99 percent) were able to swallow the capsule [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1161/abstract/53\">",
"     53",
"    </a>",
"    ]. The results obtained with the capsule sponge were compared with upper endoscopy for diagnosing Barrett's esophagus. The capsule sponge had a sensitivity of 73 percent and a specificity of 94 percent for patient with at least 1 cm of circumferential Barrett's esophagus. For patients with segments of 2 cm or more the sensitivity was 90 percent and the sensitivity was 94 percent.",
"   </p>",
"   <p>",
"    While newer technologies may allow for the detection of Barrett's esophagus using less invasive means, the question remains as to whether screening and subsequent surveillance are beneficial for patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/29/13778?source=see_link\">",
"       \"Patient information: Barrett's esophagus (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/39/2676?source=see_link\">",
"       \"Patient information: Barrett's esophagus (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3718553\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Barrett's esophagus is usually discovered during endoscopic examinations of middle-aged and older adults whose mean age at the time of diagnosis is approximately 55 years. The specialized intestinal columnar metaplasia typical of Barrett's esophagus causes no symptoms. Most patients are seen initially for symptoms of associated gastroesophageal reflux disease (GERD), such as heartburn, regurgitation, and dysphagia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two criteria must be fulfilled to make a diagnosis of Barrett's esophagus: (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The endoscopist must document that columnar epithelium lines the distal esophagus.",
"     </li>",
"     <li>",
"      Histologic examination of biopsy specimens from that columnar epithelium must reveal specialized intestinal metaplasia. Some data suggest that gastric cardia-type epithelium in the esophagus also might predispose to cancer and thus might be considered \"Barrett's esophagus,\" but most authorities still require the presence of specialized intestinal metaplasia for an unequivocal diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It has been proposed that patients with GERD symptoms should be screened endoscopically for Barrett's esophagus. We suggest that patients with at least weekly GERD symptoms that have been present for at least five years and who have multiple risk factors for esophageal adenocarcinoma undergo screening for Barrett's esophagus. However, the evidence supporting this recommendation is weak, and we feel that decisions on when to recommend endoscopic screening should be individualized. Factors known to increase the risk for Barrett's esophagus include white ethnicity, older age, obesity, and long duration of GERD symptoms. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Screening patients for Barrett's esophagus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/1\">",
"      Spechler SJ. Barrett's esophagus. Semin Gastrointest Dis 1996; 7:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/2\">",
"      Hassall E. Columnar-lined esophagus in children. Gastroenterol Clin North Am 1997; 26:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/3\">",
"      Bersentes K, Fass R, Padda S, et al. Prevalence of Barrett's esophagus in Hispanics is similar to Caucasians. Dig Dis Sci 1998; 43:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/4\">",
"      Abrams JA, Fields S, Lightdale CJ, Neugut AI. Racial and ethnic disparities in the prevalence of Barrett's esophagus among patients who undergo upper endoscopy. Clin Gastroenterol Hepatol 2008; 6:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/5\">",
"      Corley DA, Kubo A, Levin TR, et al. Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut 2009; 58:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/6\">",
"      Cook MB, Wild CP, Forman D. A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol 2005; 162:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/7\">",
"      Omer ZB, Ananthakrishnan AN, Nattinger KJ, et al. Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol 2012; 10:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/8\">",
"      Thrift AP, Pandeya N, Smith KJ, et al. The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. Aliment Pharmacol Ther 2011; 34:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/9\">",
"      Hirota WK, Loughney TM, Lazas DJ, et al. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999; 116:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/10\">",
"      Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990; 99:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/11\">",
"      Ormsby AH, Kilgore SP, Goldblum JR, et al. The location and frequency of intestinal metaplasia at the esophagogastric junction in 223 consecutive autopsies: implications for patient treatment and preventive strategies in Barrett's esophagus. Mod Pathol 2000; 13:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/12\">",
"      Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002; 123:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/13\">",
"      Ward EM, Wolfsen HC, Achem SR, et al. Barrett's esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol 2006; 101:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/14\">",
"      Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005; 129:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/15\">",
"      Sampliner RE. A population prevalence of Barrett's esophagus--finally. Gastroenterology 2005; 129:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/16\">",
"      Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003; 125:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/17\">",
"      Winters C Jr, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/18\">",
"      Spechler SJ. Clinical practice. Barrett's Esophagus. N Engl J Med 2002; 346:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/19\">",
"      Chak A, Lee T, Kinnard MF, et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 2002; 51:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/20\">",
"      Orloff M, Peterson C, He X, et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA 2011; 306:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/21\">",
"      Eloubeidi MA, Provenzale D. Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy. Am J Gastroenterol 1999; 94:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/22\">",
"      Kim SL, Waring JP, Spechler SJ, et al. Diagnostic inconsistencies in Barrett's esophagus. Department of Veterans Affairs Gastroesophageal Reflux Study Group. Gastroenterology 1994; 107:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/23\">",
"      Ronkainen J, Talley NJ, Storskrubb T, et al. Erosive esophagitis is a risk factor for Barrett's esophagus: a community-based endoscopic follow-up study. Am J Gastroenterol 2011; 106:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/24\">",
"      Kim SL, Wo JM, Hunter JG, et al. The prevalence of intestinal metaplasia in patients with and without peptic strictures. Am J Gastroenterol 1998; 93:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/25\">",
"      Riddell RH, Odze RD. Definition of Barrett's esophagus: time for a rethink--is intestinal metaplasia dead? Am J Gastroenterol 2009; 104:2588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/26\">",
"      American Gastroenterological Association, Spechler SJ, Sharma P, et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011; 140:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/27\">",
"      Spechler SJ. The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. Gastroenterology 1999; 117:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/28\">",
"      Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus--the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol 1998; 93:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/29\">",
"      Spechler SJ. Intestinal metaplasia at the gastroesophageal junction. Gastroenterology 2004; 126:567.",
"     </a>",
"    </li>",
"    <li>",
"     Fawcett DW. The esophagus and stomach. In: A Textbook of Histology, 11th ed, Bloom W, Fawcett DW (Eds), Saunders Company, Philadelphia 1986. p.619.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/31\">",
"      Amano Y, Ishimura N, Furuta K, et al. Which landmark results in a more consistent diagnosis of Barrett's esophagus, the gastric folds or the palisade vessels? Gastrointest Endosc 2006; 64:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/32\">",
"      Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C &amp; M criteria. Gastroenterology 2006; 131:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/33\">",
"      HAYWARD J. The lower end of the oesophagus. Thorax 1961; 16:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/34\">",
"      Chandrasoma P. Pathophysiology of Barrett's esophagus. Semin Thorac Cardiovasc Surg 1997; 9:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/35\">",
"      Oberg S, Peters JH, DeMeester TR, et al. Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Ann Surg 1997; 226:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/36\">",
"      Dresner SM, Griffin SM, Wayman J, et al. Human model of duodenogastro-oesophageal reflux in the development of Barrett's metaplasia. Br J Surg 2003; 90:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/37\">",
"      Sharma P, Weston AP, Morales T, et al. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia. Gut 2000; 46:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/38\">",
"      Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol 2011; 106:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/39\">",
"      Loughney T, Maydonovitch CL, Wong RK. Esophageal manometry and ambulatory 24-hour pH monitoring in patients with short and long segment Barrett's esophagus. Am J Gastroenterol 1998; 93:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/40\">",
"      Sharma P, Morales TG, Bhattacharyya A, et al. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol 1997; 92:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/41\">",
"      Weston AP, Krmpotich PT, Cherian R, et al. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. Am J Gastroenterol 1997; 92:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/42\">",
"      Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000; 132:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/43\">",
"      Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003; 138:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/44\">",
"      DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/45\">",
"      Rubenstein JH, Taylor JB. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2010; 32:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/46\">",
"      Rubenstein JH, Scheiman JM, Sadeghi S, et al. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol 2011; 106:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/47\">",
"      Lagergren J, Bergstr&ouml;m R, Lindgren A, Nyr&eacute;n O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/48\">",
"      Dulai GS, Guha S, Kahn KL, et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002; 122:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/49\">",
"      Shaheen NJ, Dulai GS, Ascher B, et al. Effect of a new diagnosis of Barrett's esophagus on insurance status. Am J Gastroenterol 2005; 100:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/50\">",
"      Shaheen NJ, Weinberg DS, Denberg TD, et al. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med 2012; 157:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/51\">",
"      ASGE Standards of Practice Committee, Evans JA, Early DS, et al. The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc 2012; 76:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/52\">",
"      Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1161/abstract/53\">",
"      Kadri SR, Lao-Sirieix P, O'Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ 2010; 341:c4372.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2269 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-2F5800EE8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_8_1161=[""].join("\n");
var outline_f1_8_1161=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3718553\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H623517391\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CANCER INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intestinal metaplasia at the GEJ and in the gastric cardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differences between long- and short-segment Barrett's",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dysplasia and adenocarcinoma in short-segment Barrett's",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SCREENING PATIENTS FOR BARRETT'S ESOPHAGUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3718356\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13951529\">",
"      - American Gastroenterological Association",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13951522\">",
"      - American College of Gastroenterology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H257927204\">",
"      - American College of Physicians",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3718363\">",
"      Alternate screening methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3718553\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2269\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2269|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/3/25662\" title=\"diagnostic image 1\">",
"      Ulceration in Barretts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2269|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/49/4895\" title=\"figure 1\">",
"      SCJ GEJ coincide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/63/11263\" title=\"figure 2\">",
"      Landmarks diagnosis Barretts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/20/36162\" title=\"figure 3\">",
"      Landmarks diagnosis of Barretts esophagus and hiatus hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2269|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/31/23024\" title=\"picture 1\">",
"      Barretts esophagectomy Gross",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/32/44557\" title=\"picture 2\">",
"      Barretts esophagus Endosc",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=related_link\">",
"      Management of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/12/8391?source=related_link\">",
"      Pathogenesis of Barrett's esophagus and its malignant transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/39/2676?source=related_link\">",
"      Patient information: Barrett's esophagus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/29/13778?source=related_link\">",
"      Patient information: Barrett's esophagus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_8_1162="Evaluation of preoperative pulmonary risk";
var content_f1_8_1162=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of preoperative pulmonary risk",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/8/1162/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/8/1162/contributors\">",
"     Gerald W Smetana, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/8/1162/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/8/1162/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/8/1162/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/8/1162/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/8/1162/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/8/1162/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative pulmonary complications contribute significantly to overall perioperative morbidity and mortality. In a study of patients undergoing elective abdominal surgery, as an example, pulmonary complications occurred significantly more often than cardiac complications and were associated with significantly longer hospital stays [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/1\">",
"     1",
"    </a>",
"    ]. The National Surgical Quality Improvement Program (NSQIP) also found that postoperative pulmonary complications were the most costly of major postoperative medical complications (including cardiac, thromboembolic, and infectious) and resulted in the longest length of stay [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The field of preoperative pulmonary evaluation is increasingly driven by evidence-based medicine, rather than expert opinion. As the impact of pulmonary complications following surgery has become increasingly apparent, estimation of their risk should be a standard element of all preoperative medical evaluations.",
"   </p>",
"   <p>",
"    The definition of postoperative pulmonary complications, pertinent anesthetic physiology, identification of patient and procedure-related risk factors, and the role of preoperative pulmonary function testing and pulmonary risk indices will be reviewed here. Strategies for reducing postoperative pulmonary complications and the evaluation of candidates for lung resection surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link\">",
"     \"Strategies to reduce postoperative pulmonary complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15400?source=see_link\">",
"     \"Preoperative evaluation for lung resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF POSTOPERATIVE PULMONARY COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported frequency of postoperative pulmonary complications in the literature varies from 2 to 70 percent. This wide range is due in part to patient selection and procedure-related risk factors, although differing definitions for postoperative complications account for much of the variability and make comparison of reported incidences across different studies difficult.",
"   </p>",
"   <p>",
"    One broad definition of postoperative pulmonary complications includes all patients with fever and either pulmonary signs, symptoms (eg, productive cough, rhonchi, or diminished breath sounds), or changes on chest x-ray (eg, atelectasis, consolidation, or incomplete expansion) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, many such liberally defined postoperative complications are of no clinical relevance.",
"   </p>",
"   <p>",
"    Another proposed definition is a pulmonary abnormality that produces identifiable disease or dysfunction that is clinically significant and adversely affects the clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/5\">",
"     5",
"    </a>",
"    ]. This would include several major categories of clinically significant complications, including [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atelectasis",
"     </li>",
"     <li>",
"      Infection, including bronchitis and pneumonia",
"     </li>",
"     <li>",
"      Prolonged mechanical ventilation and respiratory failure",
"     </li>",
"     <li>",
"      Exacerbation of underlying chronic lung disease",
"     </li>",
"     <li>",
"      Bronchospasm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rate of postoperative pulmonary complications across all types of surgery was 6.8 percent in a systematic review of studies that provided explicit outcome definitions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PERIOPERATIVE PULMONARY PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative pulmonary complications follow logically as an extension of normal perioperative pulmonary physiology. Reduced lung volume after surgery is a major factor contributing to the development of postoperative pulmonary complications.",
"   </p>",
"   <p>",
"    Thoracic and upper-abdominal surgery are associated with a reduction in lung volumes in a restrictive pattern as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vital capacity (VC) is reduced by 50 to 60 percent and may remain decreased for up to one week.",
"     </li>",
"     <li>",
"      Functional residual capacity (FRC) is reduced by about 30 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diaphragmatic dysfunction appears to play the most important role in these changes; postoperative pain and splinting are also factors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/11\">",
"     11",
"    </a>",
"    ]. Reduction of the FRC below closing volumes contributes to the risk of atelectasis, pneumonia, and",
"    <span class=\"nowrap\">",
"     ventilation/perfusion",
"    </span>",
"    <span class=\"nowrap\">",
"     (V/Q)",
"    </span>",
"    mismatching. Microatelectasis results in areas of the lung that are perfused but not ventilated, leading to impaired gas exchange with consequent postoperative hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A decrease in tidal volume, loss of sighing breaths, and increase in respiratory rate occur after abdominal and thoracic surgery and contribute to the risk of complications. In addition, residual effects of anesthesia itself and postoperative opioids both depress the respiratory drive. Inhibition of cough and impairment of mucociliary clearance of respiratory secretions are factors that contribute to the risk of postoperative infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lower abdominal surgery is associated with similar changes but to a lesser degree. Reductions in lung volumes are not seen with surgery on the extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATIENT-RELATED RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for pulmonary complications can be grouped into patient-related and procedure-related risks. The potential patient-related factors studied include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      Chronic lung disease",
"     </li>",
"     <li>",
"      Asthma",
"     </li>",
"     <li>",
"      Smoking",
"     </li>",
"     <li>",
"      General health status",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Obstructive sleep apnea",
"     </li>",
"     <li>",
"      Pulmonary hypertension",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Upper-respiratory infection",
"     </li>",
"     <li>",
"      Metabolic factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The influence of age as an independent predictor of postoperative pulmonary complications has been questioned. Early studies suggested an increased risk of pulmonary complications with advanced age [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/15\">",
"     15",
"    </a>",
"    ]. These studies, however, were not adjusted for overall health status or the presence of known pulmonary disease, and subsequent studies did not reliably demonstrate age as a predictor of postoperative complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The risk of surgical mortality was similar across age groups when stratified by American Society of Anesthesiologists (ASA) class (",
"    <a class=\"graphic graphic_table graphicRef56098 \" href=\"UTD.htm?8/33/8733\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more recent systematic review prepared for the American College of Physicians estimated the impact of age on postoperative pulmonary complications among studies that used multivariable analysis to adjust for age-related comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/8\">",
"     8",
"    </a>",
"    ]. This review made the novel observation that age &gt;50 years was an important independent predictor of risk. When compared to patients &lt;50 years old, patients aged 50 to 59 years, 60 to 69 years, 70 to 79 years, and &ge;80 years had odds ratios (OR) of 1.50 (CI 1.31-1.71), 2.28 (CI 1.86-2.80), 3.90 (CI 2.70-5.65), and 5.63 (CI 4.63-6.85), respectively. Therefore, even healthy older patients carry a substantial risk of pulmonary complications after surgery. This is in sharp contrast to perioperative cardiac risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chronic lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Known chronic lung disease is an important patient-related risk factor for postoperative pulmonary complications. Unadjusted relative risks of postoperative pulmonary complications have ranged from 2.7 to 6.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An early prospective study assessed pulmonary risk in patients with chronic obstructive pulmonary disease (COPD) as established by clinical findings and chest radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/3\">",
"     3",
"    </a>",
"    ]. Complications occurred in 26 percent of patients compared with 8 percent of controls. In another report, patients with severe COPD were six times more likely to have a major postoperative pulmonary complication after abdominal or thoracic surgery than were those without COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/20\">",
"     20",
"    </a>",
"    ]. Findings of decreased breath sounds, prolonged expiration, rales, wheezes, or rhonchi correlated with an increased risk for postoperative complications in one case control study [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/21\">",
"     21",
"    </a>",
"    ]. In a multivariate regression model, important predictors of complications were age 65 or greater (OR 1.8), smoking 40 pack-years or more (OR 1.9), and maximum laryngeal height of 4 cm or less (distance from the top of the thyroid cartilage to the suprasternal notch at end expiration, known to be an accurate sign of COPD) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more recent systematic review, however, found that impact of COPD on postoperative pulmonary complication rates was less than previously estimated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/8\">",
"     8",
"    </a>",
"    ]. Among studies that used multivariable analysis to adjust for patient-related confounders, the odds ratio for postoperative pulmonary complications was 2.36 (CI 1.90-2.93).",
"   </p>",
"   <p>",
"    Despite the increased risk of postoperative pulmonary complications in patients with obstructive lung disease, there appears to be no prohibitive level of pulmonary function below which surgery is absolutely contraindicated. This was illustrated in a study of 12 very high-risk patients as defined by older criteria of inoperability (FEV1 &lt;1 liter), only 3 of 15 surgeries were associated with postoperative complications and there were no deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/23\">",
"     23",
"    </a>",
"    ]. In another report of surgery in patients with severe COPD (FEV1 &lt;50 percent predicted), mortality was 5.6 percent (primarily related to a high mortality rate after cardiac surgery) and severe postoperative pulmonary complications occurred in 6.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/17\">",
"     17",
"    </a>",
"    ]. The benefit of surgery must be weighed against the known risks; even very high-risk patients may proceed to surgery if the indication is sufficiently compelling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite early reports indicating that patients with asthma had higher than expected rates of postoperative pulmonary complications, more recent studies have found no link for patients with well-controlled asthma. The largest such report studied 706 patients with asthma undergoing general surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/24\">",
"     24",
"    </a>",
"    ]. There were no incidents of death, pneumothorax, or pneumonia in the entire sample. Fourteen minor complications occurred including bronchospasm (12) and laryngospasm (2). One patient developed postoperative respiratory failure without sequelae. Patients with asthma who are well controlled and who have a peak flow measurement of &gt;80 percent of predicted or personal best can proceed to surgery at average risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current cigarette smokers have an increased risk for postoperative pulmonary complications even in the absence of chronic lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/3\">",
"     3",
"    </a>",
"    ]. Smokers with a greater than 20 pack-year smoking history have a higher incidence of postoperative pulmonary complications than those with a lesser pack-year history [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/25\">",
"     25",
"    </a>",
"    ]. The following observations regarding the effects of smoking on operative outcome have been noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective cohort study of 410 patients undergoing elective, noncardiac surgery found that smoking was associated with a greater than five-fold increase in the postoperative complication rate (OR = 5.5) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Retrospective, multivariate analysis of data from more than 4700 patients suggested that smoking was independently associated with an increased risk of postoperative ICU admission (OR = 1.55) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report drawn from information on 400 patients undergoing abdominal surgery, multivariate analysis found smokers to have an odds ratio of 2.3 for pulmonary complications [",
"      <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective study of 272 patients referred for medical evaluation before nonthoracic surgery that used explicit criteria for postoperative pulmonary complications found in a multivariate regression model that patients with 40 pack-years or more of smoking had an odds ratio of 1.9 for pulmonary complications&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Chronic lung disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a systematic review, the pooled odds ratio for postoperative pulmonary complications for smokers was 1.40 (95% CI 1.17-1.68) among five studies that performed multivariable analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the impact of the duration of recent cigarette smoking on complication rates remains controversial, the risk for pulmonary complications associated with smoking appears to be highest in those who have smoked within the past two months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/26,27,29,30\">",
"     26,27,29,30",
"    </a>",
"    ]. As an example, in a study of 200 patients undergoing coronary artery bypass grafting, those who had stopped smoking for two months or less had a pulmonary complication rate almost four times that of patients who had stopped for more than two months (57.1 versus 14.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/29\">",
"     29",
"    </a>",
"    ]. Patients who had stopped smoking for more than six months had rates similar to those who had never smoked (11.1 and 11.9 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic changes that accompany morbid obesity include reduction in lung volumes,",
"    <span class=\"nowrap\">",
"     ventilation/perfusion",
"    </span>",
"    mismatch, and relative hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/31\">",
"     31",
"    </a>",
"    ]. These findings might be expected to accentuate similar changes seen with anesthesia and increase the risk of pulmonary complications.",
"   </p>",
"   <p>",
"    However, obesity has not consistently been shown to be a risk factor for postoperative pulmonary complications. A review of 10 series of obese gastric bypass patients, as an example, showed a 3.9 percent incidence of pneumonia and atelectasis, a rate similar to that seen in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/31\">",
"     31",
"    </a>",
"    ]. Similarly, in a second prospective study of 117 patients undergoing thoracic surgery, there was no difference in the rate of pulmonary complications when patients were stratified by body mass index (BMI) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a prospective report of 1000 patients undergoing laparotomy found obesity, as defined by BMI &gt;25",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    to be an independent risk factor for postoperative pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, a prospective study of 400 patients undergoing abdominal surgery found obesity (BMI &gt;27",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    to be one of six independent risk factors for pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The discrepancy between these reports may arise in part because many studies do not adequately distinguish between obesity itself and comorbid conditions. A prospective study of 272 patients referred for medical evaluation before nonthoracic surgery that used explicit criteria for postoperative pulmonary complications found an odds ratio of 4.1 for pulmonary complications in patients with a BMI &ge;30",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    but in a multivariate model this ceased to be a significant factor [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/28\">",
"     28",
"    </a>",
"    ]. A systematic review found that, among eight studies using multivariate analysis, only one study identified obesity as an independent predictor [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obesity is not a significant risk factor for postoperative pulmonary complications and should not affect patient selection for otherwise high-risk procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Obstructive sleep apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea (OSA) is an emerging risk factor for postoperative pulmonary complications. It is well-appreciated in the anesthesia literature that OSA increases the risk of critical respiratory events immediately after surgery, including early hypoxemia and unplanned reintubation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link\">",
"     \"Overview of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence suggests that OSA also influences rates of complications such as pneumonia or respiratory failure. The first study to suggest risk found a higher incidence of unplanned ICU transfers and longer length of stay among patients with obstructive sleep apnea, although the study did not specifically assess rates of pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/34\">",
"     34",
"    </a>",
"    ]. A subsequent study followed 172 elective surgical patients who had clinical features suggesting OSA (snoring, excessive daytime somnolence, witnessed apneas, or crowded oropharynx) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients underwent home oximetry testing preoperatively, and were stratified on the basis of the number of oxygen desaturations per hour of at least 4 percent (ODI4%). Compared to patients with better indices, patients with an ODI4% of &gt;5 were more likely to have postoperative respiratory (8 versus 1 percent) and cardiac (4 versus 1 percent) complications. Pulmonary complications included hypoxemia, atelectasis, and pneumonia.",
"   </p>",
"   <p>",
"    The largest study to date addressing this issue evaluated 3.4 million general surgical and 2.6 million orthopedic patients from an administrative database [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients were identified with OSA based on ICD-9 coding and matched to patients without OSA based on demographics. Among general surgical procedures, patients with OSA were more likely to develop respiratory failure (OR 1.95, CI 1.91-1.98) and aspiration pneumonia (OR 1.37, CI 1.33-1.41). Comparable rates were observed for orthopedic surgery, OR 5.20 (CI 5.05-5.37) and OR 1.41 (CI 1.35-1.47), respectively. A weakness of this type of study is that the use of administrative databases tends to underestimate the presence of comorbidities such as OSA.",
"   </p>",
"   <p>",
"    In addition, OSA is common among patients undergoing certain types of surgery. In one study, investigators performed formal polysomnograms on 342 consecutive patients undergoing bariatric surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/37\">",
"     37",
"    </a>",
"    ]. OSA was present in 77 percent of patients, with 27 percent having severe OSA (apnea-hypopnea index &gt;30).",
"   </p>",
"   <p>",
"    While the literature is still emerging, we believe that clinicians should consider OSA to be a probable risk factor for pulmonary complications after surgery.",
"   </p>",
"   <p>",
"    Many patients who are preparing for surgery have undiagnosed OSA. An important question is whether patients with previously undetected OSA carry the same surgical risk as those with known OSA on treatment and whether to screen for OSA before surgery. This has important policy and resource implications for hospitals. There is currently no consensus regarding whether all or a subset of patients should be screened for OSA before surgery. Simple screening questionnaires exist to identify patients at high risk of having OSA. Screening for OSA prior to surgery is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35288?source=see_link\">",
"     \"Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hypertension increases complication rates after surgery, including in patients with mild to moderate pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/38\">",
"     38",
"    </a>",
"    ]. This appears to be true regardless of the underlying etiology of the pulmonary hypertension. As an illustration, authors studied 145 surgical patients with pulmonary hypertension, excluding those where the condition was due to left heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/39\">",
"     39",
"    </a>",
"    ]. Complications included respiratory failure (n = 41), cardiac dysrhythmia (n = 17), congestive heart failure (n = 16), renal insufficiency (n = 10), and sepsis (n = 10). Risk predictors included a history of pulmonary embolus, NYHA functional class &ge;2, intermediate or high risk surgery, and duration of anesthesia &gt;3 hours.",
"   </p>",
"   <p>",
"    A subsequent study compared 62 patients with pulmonary hypertension of any etiology to matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/40\">",
"     40",
"    </a>",
"    ]. Mortality (10 percent versus 0) and major morbidity (24 versus 3 percent) were both significantly higher among patients with pulmonary hypertension. The increased risk warrants careful consideration of indications for surgery and discussion of potential risks with patients with pulmonary hypertension.",
"   </p>",
"   <p>",
"    In one administrative database, there was a marked increase in perioperative mortality for orthopedic patients with pulmonary hypertension (n = 3543), compared to matched controls (OR 3.72, 95% CI 2.13-6.39 for hip replacement, OR 4.55, 95% CI 2.16-9.39 for knee replacement) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/41\">",
"     41",
"    </a>",
"    ]. A limitation was the use of ICD-9 coding for comorbidities which underestimates the prevalence of pulmonary hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of pulmonary complications may be higher in patients with heart failure than in those with chronic obstructive pulmonary disease. This is suggested by data from the systematic review that formed the basis of the American College of Physicians guideline, in which the pooled adjusted odds ratio for pulmonary complications were 2.93 (95% CI 1.02-8.43) for heart failure patients and 2.36 (1.90-2.93) for patients with chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The original Goldman cardiac risk index has been shown to predict postoperative pulmonary as well as cardiac complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/21\">",
"     21",
"    </a>",
"    ]. Although the Revised Cardiac Risk Index is now more commonly used to estimate risk for cardiovascular complications, validation studies of the revised index in predicting pulmonary complications have not been done. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     General health status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall health status is an important determinant of pulmonary risk. Functional dependence and impaired sensorium each increase postoperative pulmonary risk [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The commonly used American Society of Anesthesiologists (ASA) classification correlates well with pulmonary risk and is one of the most important predictors of pulmonary risk (",
"    <a class=\"graphic graphic_table graphicRef56098 \" href=\"UTD.htm?8/33/8733\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/6,16,17\">",
"     6,16,17",
"    </a>",
"    ]. The criteria for assigning ASA class include the presence of a systemic disease that affects activity or is a threat to life. Thus, patients with significant preexisting lung disease would be classified in a higher ASA class. ASA class &gt;2 confers a 4.87 fold increase in risk (95% CI",
"    <span class=\"nowrap\">",
"     3.34-7/10)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Upper respiratory infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the risk of pulmonary complications among adults undergoing high-risk surgical procedures with current or recent upper respiratory infection are limited. However, it would seem wise to defer elective surgery in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Metabolic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multifactorial risk index for postoperative respiratory failure identified two metabolic risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/42\">",
"     42",
"    </a>",
"    ]. Albumin less than 3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and blood urea nitrogen (BUN) greater than 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    each predicted risk; odds ratios were 2.53 and 2.29, respectively. A systematic review found that the magnitude of risk associated with a low serum albumin was similar to the degree of the most important patient-related risk factors and a stronger predictor of risk than an elevated BUN [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROCEDURE-RELATED RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical factors that may potentially affect pulmonary risk include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Surgical site",
"     </li>",
"     <li>",
"      Duration of surgery",
"     </li>",
"     <li>",
"      Type of anesthesia",
"     </li>",
"     <li>",
"      Type of neuromuscular blockade",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additionally, emergency surgery increases the risk for pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Surgical site",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical site is the single most important factor in predicting the overall risk of postoperative pulmonary complications; the incidence of complications is inversely related to the distance of the surgical incision from the diaphragm. Thus, the complication rate is significantly higher for thoracic and upper abdominal surgery than for lower abdominal and all other procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/7,16,27\">",
"     7,16,27",
"    </a>",
"    ]. In a systematic review of 83 univariate studies, complication rates for upper abdominal surgery, lower abdominal surgery, and esophagectomy were 19.7, 7.7, and 18.9 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/8\">",
"     8",
"    </a>",
"    ]. The higher rates of complications in upper versus lower abdominal surgery relate to the effect upon respiratory muscles and diaphragmatic function. Abdominal aortic aneurysm repair is also associated with a high risk of postoperative pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/42\">",
"     42",
"    </a>",
"    ]. Other high risk procedures include head and neck surgery and neurosurgery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laparoscopic cholecystectomy is associated with shorter recovery times, less postoperative pain, and less reduction in postoperative lung volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/8\">",
"     8",
"    </a>",
"    ]. Its impact on pulmonary complication rates is less well established. While the decrease in postoperative pain might be expected to translate into lower pulmonary complication rates, few studies have evaluated clinically important pulmonary complications as an endpoint. In a pooled analysis of 12 studies of laparoscopic versus open colon cancer surgery, there was a nonsignificant trend towards reduced pulmonary complications (OR 0.65, CI 0.28-1.49) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Duration of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical procedures lasting more than three to four hours are associated with a higher risk of pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/27,28,46,47\">",
"     27,28,46,47",
"    </a>",
"    ]. As an example, a study of risk factors for postoperative pneumonia in 520 patients found an incidence of 8 percent for surgeries lasting less than two hours versus 40 percent for procedures lasting more than four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/16\">",
"     16",
"    </a>",
"    ]. This observation suggests that, when available, a less ambitious, briefer procedure should be considered in a very high risk patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Type of anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data with regard to the pulmonary risk of spinal or epidural anesthesia when compared with general anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/48\">",
"     48",
"    </a>",
"    ]. One study, as an example, found no difference in the rate of pulmonary complications between patients undergoing transurethral prostate surgery with spinal anesthesia and those undergoing general surgery with general anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/7\">",
"     7",
"    </a>",
"    ]. These findings were confirmed in a second report of patients undergoing abdominal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, an early retrospective study of 475 men with chronic lung disease undergoing general surgery revealed a 9 percent incidence of death in the general anesthesia group compared with no deaths in the spinal anesthesia group [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/49\">",
"     49",
"    </a>",
"    ]. These findings have been subsequently supported by others [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/47\">",
"     47",
"    </a>",
"    ], including a review of high-risk patients that found that the rate of respiratory failure was significantly higher with general anesthesia than with epidural analgesia and light anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, investigators conducted the largest systematic review of this literature to date [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/51\">",
"     51",
"    </a>",
"    ]. The review evaluated the results of 141 trials that included 9559 patients. They reported a reduction in risk of pulmonary complications among patients receiving neuraxial blockade (either epidural or spinal anesthesia) with or without general anesthesia, when compared to those receiving general anesthesia alone. Patients receiving neuraxial blockade had an overall 39 percent reduction in the risk of pneumonia and a 59 percent decrease in the risk of respiratory depression. Potential limitations of the review include study heterogeneity and small sample size.",
"   </p>",
"   <p>",
"    Based upon this comprehensive review, it appears likely that general anesthesia leads to a higher risk of clinically important pulmonary complications than do epidural or spinal anesthesia, although further studies are required to confirm this observation.",
"   </p>",
"   <p>",
"    Regional nerve block is associated with lower risk and should be considered when possible for high risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/14\">",
"     14",
"    </a>",
"    ]. As an example, an axillary block with conscious sedation could be used for an upper extremity procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Type of neuromuscular blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19990?source=see_link\">",
"     Pancuronium",
"    </a>",
"    , a long-acting neuromuscular blocker, leads to a higher incidence of postoperative residual neuromuscular blockade than do shorter acting agents, and a higher incidence of postoperative pulmonary complications in those patients with residual neuromuscular blockade [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/52\">",
"     52",
"    </a>",
"    ]. Residual neuromuscular blockade is also an important risk factor for critical respiratory events in the immediate postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link\">",
"     \"Strategies to reduce postoperative pulmonary complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PREOPERATIVE RISK ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete history and physical examination are the most important elements of preoperative risk assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/21,27\">",
"     21,27",
"    </a>",
"    ]. Significant risk factors, as defined above, should be identified. Any history suggesting unrecognized chronic lung disease or heart failure, such as exercise intolerance, unexplained dyspnea, or cough, requires further consideration. It is unknown whether screening for sleep apnea will affect surgical complication rates, but it is reasonable to question obese patients about symptoms that may suggest obstructive sleep apnea prior to major surgery, in particular, the four question STOP questionnaire [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35288?source=see_link&amp;anchor=H2677200#H2677200\">",
"     \"Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea\", section on 'Patients without known OSA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical examination should be directed toward evidence for obstructive lung disease, especially noting decreased breath sounds, wheezes, rhonchi, or prolonged expiratory phase [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition, measurement of oxygen saturation by oximetry helps to stratify risk and is useful before high-risk surgeries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All candidates for lung resection should have preoperative pulmonary function tests performed (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15400?source=see_link\">",
"     \"Preoperative evaluation for lung resection\"",
"    </a>",
"    ). For all other procedures, laboratory tests serve as adjuncts to the clinical evaluation and should be obtained only in selected patients. Potential preoperative laboratory tests include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulmonary function tests (PFTs)",
"     </li>",
"     <li>",
"      Arterial blood gas analysis",
"     </li>",
"     <li>",
"      Chest radiographs",
"     </li>",
"     <li>",
"      Exercise testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is considerable debate regarding the role of preoperative pulmonary function testing for risk stratification [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/56\">",
"     56",
"    </a>",
"    ]. These tests simply confirm the clinical impression of disease severity in most cases, adding little to the clinical estimation of risk. There has also been concern that preoperative PFTs are overused and a source of wasted health care dollars [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of measures of pulmonary function have been evaluated. Bedside spirometry is widely available, and measures of the forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) have been frequently reported. Early reviews suggested criteria for increased risk that included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      FEV1 &lt;70 percent predicted",
"     </li>",
"     <li>",
"      FVC &lt;70 percent predicted",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       FEV1/FVC",
"      </span>",
"      ratio &lt;65 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two reasonable goals that could potentially justify the use of preoperative PFTs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification of a group of patients for whom the risk of the proposed surgery is not justified by the benefit.",
"     </li>",
"     <li>",
"      Identification of a subset of patients at higher risk for whom aggressive perioperative management is warranted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is little support from the literature that either of these goals is routinely met other than for lung resection surgery. As an example, in a study of patients with severe chronic obstructive lung disease (FEV1 &lt;50 percent predicted), preoperative PFTs did not predict the risk of pulmonary complications, whereas length of surgery, ASA class, and type of procedure were all significant predictors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/27\">",
"     27",
"    </a>",
"    ]. Similarly, in a case control study of 164 patients undergoing abdominal surgery, no component of spirometry predicted pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A critical review of preoperative pulmonary function testing evaluated 14 studies that met strict methodologic criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/8\">",
"     8",
"    </a>",
"    ]. Spirometric values were significant risk predictors in three of four studies that used multivariable analysis. However, other factors conferred higher odds ratios for pulmonary complications than did abnormal spirometry in two of these studies: ASA class &gt;3 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/59\">",
"     59",
"    </a>",
"    ] and chronic mucous hypersecretion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two well designed case-control studies have evaluated the benefit of PFTs as risk predictors. In a study of patients undergoing abdominal surgery, there was no difference in FEV1, FVC, or",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    between patients who had a pulmonary complication and those who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/27\">",
"     27",
"    </a>",
"    ]. In contrast, factors from the physical examination did predict risk. In a second report, investigators matched smokers with severe airflow obstruction and an FEV1 of less than 40 percent of predicted to smokers with a normal FEV1 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/61\">",
"     61",
"    </a>",
"    ]. Only bronchospasm was more common among those patients with abnormal spirometry. The incidence of postoperative pneumonia, prolonged intubation, prolonged intensive care unit stay, and death were not significantly different between the two groups.",
"   </p>",
"   <p>",
"    Few studies have compared the incremental value obtained by spirometry with the risk estimate based on clinical evaluation. Most patients with abnormal spirometry would be apparent based on history and physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on a systematic review, a 2006 American College of Physicians guideline recommends that clinicians not use preoperative spirometry routinely for predicting the risk of postoperative pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A reasonable approach to patient selection for preoperative pulmonary function testing follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain PFTs for patients with COPD or asthma if clinical evaluation cannot determine if the patient is at their best baseline and that airflow obstruction is optimally reduced. In this case, PFTs may identify patients who will benefit from more aggressive preoperative management.",
"     </li>",
"     <li>",
"      Obtain PFTs for patients with dyspnea or exercise intolerance that remains unexplained after clinical evaluation. In this case, the differential diagnosis may include cardiac disease or deconditioning. The results of PFTs may change preoperative management.",
"     </li>",
"     <li>",
"      PFTs should not be used as the primary factor to deny surgery",
"     </li>",
"     <li>",
"      PFTs should not be ordered routinely prior to abdominal surgery or other high risk surgeries",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Arterial blood gas analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;No data suggest that the finding of hypercapnia identifies high-risk patients who would not have otherwise been identified based upon established clinical risk factors. Several small case series have suggested a high risk of postoperative pulmonary complications among patients with a PaCO2 &gt;45 mmHg, a finding usually seen only in patients with severe chronic obstructive lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/14,23\">",
"     14,23",
"    </a>",
"    ]. The risk associated with this degree of PaCO2 elevation is not necessarily prohibitive, although it should lead to a reassessment of the indication for the proposed procedure and aggressive preoperative preparation.",
"   </p>",
"   <p>",
"    One study reported an association between preoperative hypoxemia and postoperative pulmonary complications among 102 patients undergoing surgery for gastric or esophageal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/62\">",
"     62",
"    </a>",
"    ]. However, hypoxemia has generally not been identified as a significant independent predictor of complications after adjustment for potential confounders.",
"   </p>",
"   <p>",
"    Current data do not support the use of preoperative arterial blood gas analyses to stratify risk for postoperative pulmonary complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Chest radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal chest x-rays are seen with increasing frequency with age. However, chest x-rays add little to the clinical evaluation in identifying healthy patients at risk for perioperative complications. As an example, one study screened 905 surgical admissions for the presence of clinical factors that were thought to be risk factors for an abnormal preoperative chest x-ray [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/63\">",
"     63",
"    </a>",
"    ]. These risk factors were age over 60 years or clinical findings consistent with cardiac or pulmonary disease. No risk factors were evident in 368 patients; of these, only one (0.3 percent) had an abnormal chest x-ray, which did not affect the surgery. On the other hand, 504 patients had identifiable risk factors; of these, 114 (22 percent) had significant abnormalities on preoperative chest x-ray. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis of studies of routine preoperative chest x-rays demonstrated a low yield for abnormalities that actually change preoperative management [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/64\">",
"     64",
"    </a>",
"    ]. Of 14,390 preoperative x-rays, there were only 140 unexpected abnormalities and only 14 cases where the chest x-ray was abnormal and influenced management.",
"   </p>",
"   <p>",
"    The prevalence of abnormal preoperative chest radiographs increases with age. As an example, in a review of studies published between 1976 and 1999, 21.1 percent of all preoperative chest radiographs were abnormal, but the prevalence of abnormal studies for patients under age 50 years old was only 4.9 percent.",
"   </p>",
"   <p>",
"    The available literature does not allow an evidence-based determination of which patients will benefit from a preoperative chest x-ray. In my opinion, it is reasonable to obtain a preoperative chest x-ray in patients with known cardiopulmonary disease and in those over age 50 years undergoing high risk surgical procedures, including upper abdominal, aortic, esophageal, and thoracic surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise testing has been studied most extensively in preparation for lung resection surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15400?source=see_link\">",
"     \"Preoperative evaluation for lung resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, cardiopulmonary exercise testing with a calculation of maximum oxygen intake and ventilatory anaerobic threshold may have a role in the evaluation of patients with unexplained dyspnea after clinical evaluation who are undergoing noncardiopulmonary surgery. In one systematic review, a majority of nine eligible studies found that both measurements predicted survival and overall postoperative complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/65\">",
"     65",
"    </a>",
"    ]. The studies did not measure postoperative pulmonary complication as a separate outcome. It is unknown to what extent this test adds value to the risk estimate obtained after a careful history and physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PULMONARY RISK INDICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac risk indices have been used widely since 1977 to stratify the risk of perioperative cardiac complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Until recently, no similar indices have been developed for risk stratification of pulmonary complications. Two important proposed pulmonary risk indices include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Multifactorial risk index for postoperative respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using a prospective cohort model that included both derivation and validation cohorts from a large Veterans Administration database, investigators developed a multifactorial risk index, the Arozullah respiratory failure index, to predict postoperative respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/42\">",
"     42",
"    </a>",
"    ]. This index is a useful adjunct to a comprehensive evaluation of risk factors that provides numerical estimates of the risk of respiratory failure; this may be helpful to both clinicians and patients. This index was modeled after the widely used cardiac risk indices. The authors evaluated those factors that predicted postoperative respiratory failure, assigning points to each predictive factor based on its strength in the multivariate analysis and developed a risk score (",
"    <a class=\"graphic graphic_table graphicRef52339 graphicRef62775 \" href=\"UTD.htm?34/39/35452\">",
"     table 2A-B",
"    </a>",
"    ). Procedure-related risk factors dominate the index with type of surgery and emergency surgery being the most important predictors. New observations in this study included the importance of abdominal aortic aneurysm repair, emergency surgery, and metabolic factors as risk factors. The same investigators reported a similar index to predict postoperative pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/45\">",
"     45",
"    </a>",
"    ]. These indices significantly advanced the field of preoperative pulmonary risk assessment. They rely upon readily available clinical information. A limitation is that most of the factors are not modifiable.",
"   </p>",
"   <p>",
"    Investigators from the same group subsequently published an updated respiratory failure index that included patients from non-Veterans Administration private sector academic institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/67\">",
"     67",
"    </a>",
"    ]. This index performed similarly well as the earlier index. However, due to its complexity and 28 independent risk factors, it is not well suited for use in clinical practice and will better serve as a tool for future research to ensure comparable patient populations.",
"   </p>",
"   <p>",
"    Another proposed risk calculator for predicting postoperative respiratory failure uses four risk factors from the American College of Physicians (ACP) guidelines (type of surgery, emergency surgery, high ASA class, and dependent functional status) and added preoperative sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94368607\">",
"    <span class=\"h2\">",
"     Risk index to predict postoperative pulmonary complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Canet Risk Index was based on a prospective evaluation of 2464 surgical patients from 59 hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/55\">",
"     55",
"    </a>",
"    ]. Postoperative pulmonary complications included respiratory infection, respiratory failure, pleural effusion, atelectasis, and bronchospasm. Some of the other reported complications were minor with minimal impact on morbidity (eg, new wheezing treated with bronchodilators). Based on the strength of the association between potential risk factors and outcomes after multivariable adjustment, seven independent risk factors emerged, each with a weighted point score (",
"    <a class=\"graphic graphic_table graphicRef76906 \" href=\"UTD.htm?10/13/10461\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Advanced age",
"     </li>",
"     <li>",
"      Low preoperative oxygen saturation",
"     </li>",
"     <li>",
"      Respiratory infection within the past month",
"     </li>",
"     <li>",
"      Preoperative anemia",
"     </li>",
"     <li>",
"      Upper-abdominal or thoracic surgery",
"     </li>",
"     <li>",
"      Surgery lasting more than two hours",
"     </li>",
"     <li>",
"      Emergency surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The index accurately stratified risk. In the validation cohort, low-, intermediate-, and high-risk patients had pulmonary complication rates of 1.6, 13.3, and 42.2 percent, respectively.",
"   </p>",
"   <p>",
"    This index reconfirms many of the established risk factors according to the ACP guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?1/8/1162/abstract/8\">",
"     8",
"    </a>",
"    ] and adds novel factors of anemia and low oxygen saturation. Advantages of this index include its simplicity and the use of readily available clinical information. The principal disadvantage is the inclusion of minor complications of minimal clinical significance to outcomes. Although this index has not been validated in large populations, we find it a useful tool to stratify risk when advising patients before surgery and to identify those patients most likely to benefit from risk-reduction interventions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link\">",
"     \"Strategies to reduce postoperative pulmonary complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postoperative pulmonary complications are an important source of perioperative morbidity and mortality. They represent an extension of the normal physiologic changes in the lung that occur with anesthesia. Definite risk factors for these complications include the following: age &gt;50 years, chronic obstructive lung disease, congestive heart failure, poor general health status (ASA class &gt;2), functional dependence, obstructive sleep apnea, pulmonary hypertension, low oxygen saturation, serum albumin &lt;35",
"      <span class=\"nowrap\">",
"       gm/L,",
"      </span>",
"      surgery lasting greater than three hours, emergency surgery, use on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19990?source=see_link\">",
"       pancuronium",
"      </a>",
"      as a neuromuscular blocker, and upper abdominal, thoracic, aortic, head and neck, neurosurgery, and abdominal aortic aneurysm surgery. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patient-related risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Procedure-related risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Probable risk factors include the following: general anesthesia (compared to spinal or epidural anesthesia), PaCO2 &gt;45 mmHg, abnormal chest radiograph, cigarette use within the previous eight weeks, and current upper respiratory tract infection. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patient-related risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Procedure-related risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A careful history and physical examination are the most important tools for preoperative risk assessment in evaluating patients for potential postoperative pulmonary complications. Attention should be paid to symptoms that suggest the possibility of occult underlying lung disease, including exercise intolerance, cough, and unexplained dyspnea. In addition, the clinician should seek a history of the risk factors for postoperative pulmonary complications. A high-risk patient will benefit from aggressive strategies to reduce pulmonary complications (",
"      <a class=\"graphic graphic_algorithm graphicRef56866 \" href=\"UTD.htm?20/57/21393\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Preoperative risk assessment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link\">",
"       \"Strategies to reduce postoperative pulmonary complications\"",
"      </a>",
"      .) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Both the Arozullah and Canet indices provide a simplified approach to preoperative pulmonary risk estimation and are useful tools to stratify risk and to identify those patients most likely to benefit from risk-reduction interventions. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Pulmonary risk indices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All candidates for lung resection should have preoperative pulmonary function tests performed. For all other procedures, laboratory tests serve as adjuncts to the clinical evaluation and should be obtained only in selected patients. Potential preoperative laboratory tests include pulmonary function tests (PFTs), chest radiographs, and exercise testing.",
"      <br/>",
"      <br/>",
"      In patients undergoing high-risk surgery who are over age 50 years, or who have cardiac or pulmonary disease suggested by the clinical evaluation, a chest radiograph within the past six months is needed. Pulmonary function tests should be reserved for patients with uncharacterized dyspnea or exercise intolerance and for those with COPD or asthma where clinical evaluation cannot determine if airflow obstruction has been optimally reduced. The benefit of PFTs in other situations is unproven. There is no role for preoperative arterial blood gas analyses to identify high-risk patients or to deny surgery. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Preoperative risk assessment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/1\">",
"      Lawrence VA, Hilsenbeck SG, Mulrow CD, et al. Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery. J Gen Intern Med 1995; 10:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/2\">",
"      Dimick JB, Chen SL, Taheri PA, et al. Hospital costs associated with surgical complications: a report from the private-sector National Surgical Quality Improvement Program. J Am Coll Surg 2004; 199:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/3\">",
"      Wightman JA. A prospective survey of the incidence of postoperative pulmonary complications. Br J Surg 1968; 55:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/4\">",
"      Mohr DN, Jett JR. Preoperative evaluation of pulmonary risk factors. J Gen Intern Med 1988; 3:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/5\">",
"      O'Donohue WJ Jr. Postoperative pulmonary complications. When are preventive and therapeutic measures necessary? Postgrad Med 1992; 91:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/6\">",
"      Hall JC, Tarala RA, Hall JL, Mander J. A multivariate analysis of the risk of pulmonary complications after laparotomy. Chest 1991; 99:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/7\">",
"      Gracey DR, Divertie MB, Didier EP. Preoperative pulmonary preparation of patients with chronic obstructive pulmonary disease: a prospective study. Chest 1979; 76:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/8\">",
"      Smetana GW, Lawrence VA, Cornell JE, American College of Physicians. Preoperative pulmonary risk stratification for noncardiothoracic surgery: systematic review for the American College of Physicians. Ann Intern Med 2006; 144:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/9\">",
"      Meyers JR, Lembeck L, O'Kane H, Baue AE. Changes in functional residual capacity of the lung after operation. Arch Surg 1975; 110:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/10\">",
"      Craig DB. Postoperative recovery of pulmonary function. Anesth Analg 1981; 60:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/11\">",
"      Ford GT, Whitelaw WA, Rosenal TW, et al. Diaphragm function after upper abdominal surgery in humans. Am Rev Respir Dis 1983; 127:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/12\">",
"      Marshall BE, Wyche MQ Jr. Hypoxemia during and after anesthesia. Anesthesiology 1972; 37:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/13\">",
"      Sugimachi K, Ueo H, Natsuda Y, et al. Cough dynamics in oesophageal cancer: prevention of postoperative pulmonary complications. Br J Surg 1982; 69:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/14\">",
"      Tisi GM. Preoperative evaluation of pulmonary function. Validity, indications, and benefits. Am Rev Respir Dis 1979; 119:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/15\">",
"      Djokovic JL, Hedley-Whyte J. Prediction of outcome of surgery and anesthesia in patients over 80. JAMA 1979; 242:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/16\">",
"      M&oslash;ller AM, Maal&oslash;e R, Pedersen T. Postoperative intensive care admittance: the role of tobacco smoking. Acta Anaesthesiol Scand 2001; 45:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/17\">",
"      Kroenke K, Lawrence VA, Theroux JF, Tuley MR. Operative risk in patients with severe obstructive pulmonary disease. Arch Intern Med 1992; 152:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/18\">",
"      Thomas DR, Ritchie CS. Preoperative assessment of older adults. J Am Geriatr Soc 1995; 43:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/19\">",
"      Smetana GW. Preoperative pulmonary evaluation. N Engl J Med 1999; 340:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/20\">",
"      Kroenke K, Lawrence VA, Theroux JF, et al. Postoperative complications after thoracic and major abdominal surgery in patients with and without obstructive lung disease. Chest 1993; 104:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/21\">",
"      Lawrence VA, Dhanda R, Hilsenbeck SG, Page CP. Risk of pulmonary complications after elective abdominal surgery. Chest 1996; 110:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/22\">",
"      Straus SE, McAlister FA, Sackett DL, Deeks JJ. The accuracy of patient history, wheezing, and laryngeal measurements in diagnosing obstructive airway disease. CARE-COAD1 Group. Clinical Assessment of the Reliability of the Examination-Chronic Obstructive Airways Disease. JAMA 2000; 283:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/23\">",
"      Milledge JS, Nunn JF. Criteria of fitness for anaesthesia in patients with chronic obstructive lung disease. Br Med J 1975; 3:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/24\">",
"      Warner DO, Warner MA, Barnes RD, et al. Perioperative respiratory complications in patients with asthma. Anesthesiology 1996; 85:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/25\">",
"      Warner MA, Divertie MB, Tinker JH. Preoperative cessation of smoking and pulmonary complications in coronary artery bypass patients. Anesthesiology 1984; 60:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/26\">",
"      Bluman LG, Mosca L, Newman N, Simon DG. Preoperative smoking habits and postoperative pulmonary complications. Chest 1998; 113:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/27\">",
"      Brooks-Brunn JA. Predictors of postoperative pulmonary complications following abdominal surgery. Chest 1997; 111:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/28\">",
"      McAlister FA, Khan NA, Straus SE, et al. Accuracy of the preoperative assessment in predicting pulmonary risk after nonthoracic surgery. Am J Respir Crit Care Med 2003; 167:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/29\">",
"      Warner MA, Offord KP, Warner ME, et al. Role of preoperative cessation of smoking and other factors in postoperative pulmonary complications: a blinded prospective study of coronary artery bypass patients. Mayo Clin Proc 1989; 64:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/30\">",
"      Nakagawa M, Tanaka H, Tsukuma H, Kishi Y. Relationship between the duration of the preoperative smoke-free period and the incidence of postoperative pulmonary complications after pulmonary surgery. Chest 2001; 120:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/31\">",
"      Pasulka PS, Bistrian BR, Benotti PN, Blackburn GL. The risks of surgery in obese patients. Ann Intern Med 1986; 104:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/32\">",
"      Dales RE, Dionne G, Leech JA, et al. Preoperative prediction of pulmonary complications following thoracic surgery. Chest 1993; 104:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/33\">",
"      Gross JB, Bachenberg KL, Benumof JL, et al. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. Anesthesiology 2006; 104:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/34\">",
"      Gupta RM, Parvizi J, Hanssen AD, Gay PC. Postoperative complications in patients with obstructive sleep apnea syndrome undergoing hip or knee replacement: a case-control study. Mayo Clin Proc 2001; 76:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/35\">",
"      Hwang D, Shakir N, Limann B, et al. Association of sleep-disordered breathing with postoperative complications. Chest 2008; 133:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/36\">",
"      Memtsoudis S, Liu SS, Ma Y, et al. Perioperative pulmonary outcomes in patients with sleep apnea after noncardiac surgery. Anesth Analg 2011; 112:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/37\">",
"      Sareli AE, Cantor CR, Williams NN, et al. Obstructive sleep apnea in patients undergoing bariatric surgery--a tertiary center experience. Obes Surg 2011; 21:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/38\">",
"      Price LC, Montani D, Ja&iuml;s X, et al. Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension. Eur Respir J 2010; 35:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/39\">",
"      Ramakrishna G, Sprung J, Ravi BS, et al. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality. J Am Coll Cardiol 2005; 45:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/40\">",
"      Lai HC, Lai HC, Wang KY, et al. Severe pulmonary hypertension complicates postoperative outcome of non-cardiac surgery. Br J Anaesth 2007; 99:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/41\">",
"      Memtsoudis SG, Ma Y, Chiu YL, et al. Perioperative mortality in patients with pulmonary hypertension undergoing major joint replacement. Anesth Analg 2010; 111:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/42\">",
"      Arozullah AM, Daley J, Henderson WG, Khuri SF. Multifactorial risk index for predicting postoperative respiratory failure in men after major noncardiac surgery. The National Veterans Administration Surgical Quality Improvement Program. Ann Surg 2000; 232:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/43\">",
"      Qaseem A, Snow V, Fitterman N, et al. Risk assessment for and strategies to reduce perioperative pulmonary complications for patients undergoing noncardiothoracic surgery: a guideline from the American College of Physicians. Ann Intern Med 2006; 144:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/44\">",
"      Smetana GW, Macpherson DS. The case against routine preoperative laboratory testing. Med Clin North Am 2003; 87:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/45\">",
"      Arozullah AM, Khuri SF, Henderson WG, et al. Development and validation of a multifactorial risk index for predicting postoperative pneumonia after major noncardiac surgery. Ann Intern Med 2001; 135:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/46\">",
"      Celli BR, Rodriguez KS, Snider GL. A controlled trial of intermittent positive pressure breathing, incentive spirometry, and deep breathing exercises in preventing pulmonary complications after abdominal surgery. Am Rev Respir Dis 1984; 130:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/47\">",
"      Pedersen T, Eliasen K, Henriksen E. A prospective study of risk factors and cardiopulmonary complications associated with anaesthesia and surgery: risk indicators of cardiopulmonary morbidity. Acta Anaesthesiol Scand 1990; 34:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/48\">",
"      Cohen MM, Duncan PG, Tate RB. Does anesthesia contribute to operative mortality? JAMA 1988; 260:2859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/49\">",
"      Tarhan S, Moffitt EA, Sessler AD, et al. Risk of anesthesia and surgery in patients with chronic bronchitis and chronic obstructive pulmonary disease. Surgery 1973; 74:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/50\">",
"      Yeager MP, Glass DD, Neff RK, Brinck-Johnsen T. Epidural anesthesia and analgesia in high-risk surgical patients. Anesthesiology 1987; 66:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/51\">",
"      Rodgers A, Walker N, Schug S, et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ 2000; 321:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/52\">",
"      Berg H, Roed J, Viby-Mogensen J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997; 41:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/53\">",
"      Murphy GS, Szokol JW, Marymont JH, et al. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg 2008; 107:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/54\">",
"      Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology 2008; 108:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/55\">",
"      Canet J, Gallart L, Gomar C, et al. Prediction of postoperative pulmonary complications in a population-based surgical cohort. Anesthesiology 2010; 113:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/56\">",
"      Lawrence VA, Page CP, Harris GD. Preoperative spirometry before abdominal operations. A critical appraisal of its predictive value. Arch Intern Med 1989; 149:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/57\">",
"      De Nino LA, Lawrence VA, Averyt EC, et al. Preoperative spirometry and laparotomy: blowing away dollars. Chest 1997; 111:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/58\">",
"      Gass GD, Olsen GN. Preoperative pulmonary function testing to predict postoperative morbidity and mortality. Chest 1986; 89:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/59\">",
"      Wong DH, Weber EC, Schell MJ, et al. Factors associated with postoperative pulmonary complications in patients with severe chronic obstructive pulmonary disease. Anesth Analg 1995; 80:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/60\">",
"      Fuso L, Cisternino L, Di Napoli A, et al. Role of spirometric and arterial gas data in predicting pulmonary complications after abdominal surgery. Respir Med 2000; 94:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/61\">",
"      Warner DO, Warner MA, Offord KP, et al. Airway obstruction and perioperative complications in smokers undergoing abdominal surgery. Anesthesiology 1999; 90:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/62\">",
"      Fan ST, Lau WY, Yip WC, et al. Prediction of postoperative pulmonary complications in oesophagogastric cancer surgery. Br J Surg 1987; 74:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/63\">",
"      Rucker L, Frye EB, Staten MA. Usefulness of screening chest roentgenograms in preoperative patients. JAMA 1983; 250:3209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/64\">",
"      Archer C, Levy AR, McGregor M. Value of routine preoperative chest x-rays: a meta-analysis. Can J Anaesth 1993; 40:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/65\">",
"      Smith TB, Stonell C, Purkayastha S, Paraskevas P. Cardiopulmonary exercise testing as a risk assessment method in non cardio-pulmonary surgery: a systematic review. Anaesthesia 2009; 64:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/66\">",
"      Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med 1977; 297:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/67\">",
"      Johnson RG, Arozullah AM, Neumayer L, et al. Multivariable predictors of postoperative respiratory failure after general and vascular surgery: results from the patient safety in surgery study. J Am Coll Surg 2007; 204:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/8/1162/abstract/68\">",
"      Gupta H, Gupta PK, Fang X, et al. Development and validation of a risk calculator predicting postoperative respiratory failure. Chest 2011; 140:1207.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6917 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_8_1162=[""].join("\n");
var outline_f1_8_1162=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF POSTOPERATIVE PULMONARY COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PERIOPERATIVE PULMONARY PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATIENT-RELATED RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chronic lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      General health status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Upper respiratory infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Metabolic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROCEDURE-RELATED RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Surgical site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Duration of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Type of anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Type of neuromuscular blockade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PREOPERATIVE RISK ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Arterial blood gas analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Chest radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Exercise testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PULMONARY RISK INDICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Multifactorial risk index for postoperative respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94368607\">",
"      Risk index to predict postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6917\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6917|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/57/21393\" title=\"algorithm 1\">",
"      Risk postop pulm complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6917|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/33/8733\" title=\"table 1\">",
"      American Society of Anesthesiologists physical status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/8/10379\" title=\"table 2A\">",
"      Performance Arozullah index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/57/41883\" title=\"table 2B\">",
"      Arozullah index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/13/10461\" title=\"table 3\">",
"      Postop complication predictors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15400?source=related_link\">",
"      Preoperative evaluation for lung resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35288?source=related_link\">",
"      Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_8_1163="Definition of prematurity based on birth weights";
var content_f1_8_1163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definition of prematurity based on birth weights",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Birth weight, grams",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Abbreviation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;2500",
"       </td>",
"       <td>",
"        Low birth weight",
"       </td>",
"       <td>",
"        LBW",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;1500",
"       </td>",
"       <td>",
"        Very low birth weight",
"       </td>",
"       <td>",
"        VLBW",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;1000",
"       </td>",
"       <td>",
"        Extremely low birth weight",
"       </td>",
"       <td>",
"        ELBW",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_8_1163=[""].join("\n");
var outline_f1_8_1163=null;
var title_f1_8_1164="Initiation protocol NPPV";
var content_f1_8_1164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Protocol for initiation of noninvasive positive pressure ventilation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Appropriately monitored location, oximetry, respiratory impedance, vital signs as clinically indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Patient in bed or chair at &gt;30 angle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Select and fit interface",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Select ventilator",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Apply headgear; avoid excessive strap tension (one or two fingers under strap)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Connect interface to ventilator tubing and turn on ventilator",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Start with low pressure in spontaneously triggered mode with backup rate; pressure limited: 8 to 12 cm H2O inspiratory pressure; 3 to 5 cm H2O expiratory pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Gradually increase inspiratory pressure (10 to 20 cm H2O) as tolerated to achieve alleviation of dyspnea, decreased respiratory rate, increased tidal volume (if being monitored), and good patient-ventilator synchrony",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Provide O2 supplementation as need to keep O2 sat &gt;90 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. Check for air leaks, readjust straps as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11. Add humidifier as indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12. Consider mild sedation (eg, intravenously administered lorazepam 0.5 mg) in agitated patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13. Encouragement, reassurance, and frequent checks and adjustments as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14. Monitor occasional blood gases (within 1 to 2 hours) and then as needed",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from International Concensus Conferences in Intensive Care Medicine: Noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 2001; 163:288. Copyright &copy; 2001 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_8_1164=[""].join("\n");
var outline_f1_8_1164=null;
var title_f1_8_1165="Mgmt interleukin 2 toxicity I";
var content_f1_8_1165=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of IL-2 toxicity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Hypotension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Minimal fluid resuscitation to avoid fluid overload.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Normally systolic blood pressure (SBP) is 20-30 mmHg lower than baseline but patient is asymptomatic. In younger patients, may tolerate SBP 80 mmHg; in older patients, may tolerate SBP 85-90mmHg, depending on baseline. If baseline is higher, may maintain SBP at 100 mmHg.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Although saline may be utilized initially, it should be used judiciously to avoid fluid overload and extensive capillary leak.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Colloid administration may be necessary if SBP is lower, for symptomatic hypotension, or if urine output declines.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Pressors, either dopamine, 1-6 microg/kg/min (if not tachycardic) or phenylephrine, 0.1-2.0 microg/kg/min, maybe used to stabilize blood pressure.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Patients routinely gain 4.5 kg (10 lbs) in water weight.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Cardiac arrhythmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Sinus tachycardia is common and may reflect maximal toxicity between doses, or a reaction to hypotension or dopamine administration. Extension of time between doses may control this.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Supraventricular tachycardia may occur with therapy and may require treatment depending on rate. Therapy can be continued once this is controlled, by extending time between doses. If this occurs near the end of the course of treatment, treatment should probably be discontinued.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. IL-2 doses should be withheld for atrial fibrillation, but may be resumed when conversion to sinus rhythm is accomplished and the patient is hemodynamically stable.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. If significant (ventricular) arrhythmias occur during treatment, IL-2 should be held and an evaluation for cardiac damage must be undertaken, for ischemia or infarction.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Although isolated premature ventricular contractions may not signal discontinuation of IL-2, if they increase in frequency or become sustained, IL-2 therapy should be stopped.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Metabolic acidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Metabolic acidosis may occur with reductions in serum bicarbonate.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Sodium bicarbonate should be utilized to maintain serum HCO3 above 18 meq/L.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. If bicarbonate is persistently low, IL-2 should be held.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Fevers/chills",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. These can be prevented to some extent by premedication with acetaminophen, 650 mg orally every 4 hr, and indomethacin, 25 mg orally every 6 hr throughout IL-2 administration. H-2 blockers should be administered to protect the gastric mucosa.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Patients who develop dose-related significant shaking chills, usually 30-90 min following the dose, should receive intravenous meperidol (pethidine) 25-50 mg to stop them. They may then need prochlorperazine for nausea.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Nausea/vomiting",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Although not occurring in all patients, we routinely provide premedication daily with 5HT3 antagonists (eg, ondansetron), as well as prochlorperazine for dose-relate nausea. Dexamethasone is not routinely given.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dutcher J, Atkins MB, Margolin K, et al for the Cytokine Working Group. Kidney Cancer: The Cytokine Working Group Experience (1986-2001), part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol 2001; 18:209. Copyright &copy; 2001 Humana Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_8_1165=[""].join("\n");
var outline_f1_8_1165=null;
var title_f1_8_1166="Gemeprost and misoprostol";
var content_f1_8_1166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gemeprost and misoprostol",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 449px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_8_1166=[""].join("\n");
var outline_f1_8_1166=null;
var title_f1_8_1167="S-nitrosothiols effect on NTS";
var content_f1_8_1167=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Effect of S-nitrosothiols on minute ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 240px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) V",
"    <sub>",
"     E",
"    </sub>",
"    during (shaded) and following a short period of hypoxia.",
"    <br/>",
"    (B) Injection of 1 nmol into the NTS resulted in marked increase in V",
"    <sub>",
"     E",
"    </sub>",
"    (injection indicated by red arrow) with onset and decay characteristics identical to those observed during short exposure of the whole animal to hypoxia and return to nomoxia.",
"    <div class=\"footnotes\">",
"     SNOs: S-nitrosothiols; V",
"     <sub>",
"      E",
"     </sub>",
"     : minute ventilation; NTS: nucleus tractus solitarius.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lipton AJ, Johnson MA, MacDonald T, et al. S-Nitrosothiols signal the ventilatory response to hypoxia. Nature 2001; 413:171. Copyright &copy; 2001 Nature.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_8_1167=[""].join("\n");
var outline_f1_8_1167=null;
